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Summary
A suitable Tn5 delivery vector for mutagenesis of the pathogen 
Bordetella pert ussis was identified as the Collb-based plasmid pLG221. 
Insertion mutants, created using this 'suicide' vector, were screened 
for the loss of virulence-associated properties, or virulence- 
regulatory functions. No mutants were identified as having lost the 
heat-labile toxin alone. Additionally, no mutants were identified as 
being unable to modulate under C-mode growth conditions. However, a 
number of mutants were identified as being unable to bind the dye 
Congo red (a property associated with the avirulent phenotype). 
Several of these strains were subsequently shown to exhibit a 
pleiotropically negative phenotype for the expression of virulence- 
associated factors.
The events causing the avirulent phenotype in the Crb" mutants 
were initially examined by Identification of the Tn5 Insertion sites. 
Two mutants were shown to have Tn5 insertions within a region with 
BamHI. Sail and EcoRI restriction fragments identical to the map'of 
the bvg locus. However, no clustering of transposon insertions, 
indicative of an alternate virulence regulatory locus, were noted 
between the other mutants.
Complementation studies, introducing the cloned bvg locus into 
the Crb" mutants, returned virulence-associated properties to all the 
mutants, suggesting that the avirulent phenotype could only be created 
by mutations in the bvg locus, Hybridisation of radiolabelled pRMB2 
DNA (which contains the cloned bvg locus) to Southern blots of the 
Crb" mutant's DNA identified deletions of this region in two mutants.
- XXV -
Mutants not showing obvious genetic rearrangements in the bvg locus 
were considered to have been caused by frameshlft mutations (as 
previously identified in the Tohama strain). This idea was examined by 
using the frameshift mutagen ICR 191 to create Crb+ revertants. 
However, only a single mutant was shown to revert to virulent 
characteristics after such treatment. Therefore, the events causing 
the loss of virulence-associated characteristics in the mutants 
created in this study were defined in only five of the ten Isolates.
A single mutant (strain 51) showing the Crb“ phenotype was shown 
to be haeraolytic, while not producing other virulence-associated 
factors. This mutant was shown to be avirulent in an infant mouse 
model. Initial studies have also indicated that a vaccine made from 
Tn5 mutant 51 showed some protective activity against intranasal 
challenge in Infant mice, although not against intracerebral 
challenge.
- xxvi -
INTRODUCTION
1.1 The Bordetellae
The Gram-negative cocco-bacillus Bordetella pertussis is the main 
cause of the severe respiratory tract infection "pertussis" in human 
infants. Pertussis, or whooping cough, has been recognised as a 
clinical entity for several centuries with the causative bacterium 
first cultured by Bordet and Gengou (1906). The organism was 
originally classified in the genus Haemophilus because of a 
requirement for blood in the culture medium. However, B. pertussis has 
been shown to be able to grow on relatively simple media, with either 
blood, charcoal, soluble starch or anionic-exchange resins added to 
overcome the effects of growth inhibitors. Stainer and Scholte (1971) 
identified a simple, chemically-defined medium suitable for the large- 
scale culture of B. pertussis, which, with the addition of heptakis 
(2,6-0-dimethyl) p-cyclodextrln CImalzumi et al,, 1983), allows growth 
from small inocula.
The genus Bordetella includes three other species which are also 
respiratory tract pathogens. B. parapertussis (Linneman and Ferry, 
1977) has been implicated as the cause of a mild form of pertussis in 
humans. B, hronchlseptica (Goodnow, 1980) causes respiratory tract 
infections in certain other mammals, including kennel cough in dogs 
and atrophic rhinitis in swine. The recently reclassified B. avium 
(Kersters et al., 1984) is the agent of coryza in turkey poults.
Hybridisation analysis of B. pertussis, B. parapertussis and 
B. hronchlseptica chromosomal DNAs has indicated a close genetic 
relatedness of these species (Kloos et al., 1981). Studies on the 
electrophoretic mobilities of 15 metabolic enzymes of these
- 2 -
bordetellae (Musser et al,, 1986) divided the genus into three groups. 
The first group contained all B, broncblseptica strains; the second 
group was composed of all B. parapertussis strains and B. pertussis 
strain 18-323; the third group contained the remaining B. pertussis 
strains. This grouping of B. pertussis 18-323 with B. parapertussis 
strains has been disputed by the work of McPheat and McNally (1987a) 
who identified a repeated DNA sequence of approximately Ikb from the 
genome of B. pertussis. This repeat sequence was shown to be absent in 
B. parapertussis and B. bronchiseptica, but was present In B. pertussis 
strain 18-323 (Fig. 1), Aricô et al. (1987) and Gross et al. (1989a) 
have discussed the possible evolutionary relatedness of the 
bordetellae based on the nucleotide sequence of the pertussis toxin 
operon (Fig. 1). According to this data B. avium is the most distant 
relative of B. pertussis since pertussis toxin genes are not present in 
this species. Both B. parapertussis and B. bronchiseptica possess 
mutated toxin genes, but B. pertussis strains alone produce pertussis 
toxin.
1.11 Pertussis
Wardlaw and Parton (1988) in their review of the host-paraslte 
relationship state that "B. pertussis must be a very well adapted 
parasite with highly effective mechanisms for its own transmission and 
survival". The bacteria attach specifically to the cilia of the 
epithelial cells of the respiratory tract where they multiply and 
initially cause symptoms resembling those of the common cold. The 
subsequent paroxysmal phase of the disease is marked by the onset of 
the characteristic whoop, caused by the rush of air over a partially
Fig. 1 Phylogenetic tree of the bordetellae
The phylogenetic tree of Gross et al. (1989a) based on the 
nucleotide sequence of the pertussis toxin operon Indicates (1) 
the acquisition of the pertussis toxin operon after B. avium has 
split away from the other bordetellae, and (2) the gain of 
ability to express pertussis toxin found in B. pertussis. 
B.pertussis 18-323 appears to be an evolutionary link between 
B. parapertussis and B. pertussis clinical isolates, since it 
shares properties in common with both species (Musser et al. , 
1986; McPheat and McNally, 1987a).
- 4 -
6.  av ium
B . b r o n c h i s e p t i c a
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B. p e r t u s s i s  18323
B. p e r t u s s i s  - c l i n i c a l  i sola t es
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closed glottis. Patients may exhibit pathophysiological changes
including leukocytosis with a predominance of lymphocytes, weight 
loss, occasional hypoglycaemia and, rarely, encephalopathy [see Walker 
(1988) for clinical aspects of pertussis].
During the course of the disease the organisms do not enter the 
blood stream, and the isolation rate for B. pertussis drops
progressively after the onset of the paroxysmal phase. The inability 
to culture the organism during the most severe stage of the disease 
led to the hypothesis that the majority of clinical symptoms are due 
to long-acting, systemically disseminated toxin(s) produced by the 
bacteria (Pittman, 1984). B. pertussis produces a wide variety of
virulence-associated factors, toxins and adhesins, which have been 
assigned roles in the disease process, promoting a fuller
understanding of pathogenicity of pertussis (Robinson et al. , 1985a;
Weiss and Hewlett, 1986). A description of these factors is given in 
the next section.
No generally accepted effective treatment for pertussis is 
available. Broad-spectrum antibiotics given during the early stages'of 
the disease are effective against the bacterium, but have little or no 
effect on the clinical course of the established disease. Erythromycin 
may reduce infectivity (Bass, 1983), and has been used in conjunction 
with glucocorticoids which have been reported to ease coughing and
shorten the duration of the disease (Barrie, 1982; Dianese, 1982).
l.ill Virulence Factors of B. pertussis
l.iil.a. Adenylate cvclase and haemolysin
B. pertussis produces a mainly extracytoplasmic adenylate cyclase
— 6 —
(AC) (Hewlett and Wolff, 1976), which is stimulated by the eukaryotic 
calcium-binding protein calmodulin (Wolff et al., 1980). Two forms of 
the enzyme have been identified; i. the adenylate cyclase enzyme, 
which converts ATP -> cAMP (Hewlett et al. , 1976), and il, the
adenylate cyclase toxin (ACT), which can enter eukaryotic cells to 
catalyse the above reaction, thereby impairing cellular function 
(Including the activities of phagocytes) (Confer and Eaton, 1982). 
Hewlett and Gordon (1988) have suggested that ACT may conform to the 
A-B subunit model of toxins (Gill, 1978).
B. pertussis also produces a haemolysin (HLY). Weiss et al. (1983) 
suggested that the genes which express HLY and AC are linked on an 
operon, since a single insertion of TnS' in BP348 Csee Section 
l.vili.d.] caused the simultaneous loss of both factors. The close 
association of these genes was confirmed by Brownlie et al, (1986), 
using a recombinant plasmid (pRMBl) which restored AC and HLY activity 
to BP348. The LAFRl-derlved cosmid pRMBl has been mapped (Fig. 2) and 
subcloned (Brownlie et al., 1988). Glaser et al. (1988a) cloned, 
expressed and sequenced the adenylate cyclase operon. The 1250 
carboxy-terminal amino-acids of the protein were found to have 
significant homology to both E. coli a-haemolysin and Pasteurella 
haemolytica leucotoxin (Glaser et al., 1988b), suggesting that AC and 
HLY activities are conferred by the same protein, the adenylate 
cyclase toxin or cyclolysin, in B. pertussis.
A similar calmodulin-dependent, extracellular ACT (composed of 
the oedema factor and protective antigen) has been identified in 
Bacillus anthracis CLeppla, 1982). The enzyme kinetics of this toxin, 
and requirement for divalent cations, resemble those of the
-  7 -
Fig. 2 Restriction map of the cosmid pRMBl
The recombinant plasmid pRMBl is composed of the broad-host- 
range vector pLAFRl and the cloned adenylate cyclase and 
haemolysin determinants (Brownlie et al., 1988). Transposon
insertions in mutants showing the loss of HLY (BP349), or AC and 
HLY (BP348), have been mapped to the lOkb BamHl fragment as 
indicated (Brownlie et al., 1988; Glaser et al,, 1988b). The 
5.5kb Clal fragment present in the subclone pRMBll is also shown 
and contains both the start of the cyaA open reading frame and, 
approximately 3kb upstream, the repeat sequence IS481vl (McPheat 
et al., 1989).
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B.pertussis ACT (Leppla, 1984). Additionally, the central region of 
the B. anthracis adenylate cyclase includes an area of good homology 
with the N-terminal part of the B. pertussis enzyme (Escuyer et al., 
1988), suggesting that these cyclases have originated from a common 
ancestor. However, Hewlett and Gordon (1988) have suggested that these 
analogous toxins are Immunologically and functionally distinct.
A transposon mutant of B. pertussis unable to express the 
adenylate cyclase operon [BP348; see Section l.vili.d.] has been shown 
to have reduced virulence in mice after intracerebral or intranasal 
challenge (Weiss et al., 1983; Ôlander et al. , 1986), indicating that
this toxin is an important virulence factor. Brézin et al. (1987) 
incubated a challenge inoculum with a monoclonal anti-AC antibody and 
showed that this protected mice from respiratory infection, again 
indicating the ACT to be a major toxin. The ACT has been suggested as 
a possible candidate for Inclusion in acellular vaccines (Novotny et 
al., 1985).
1.iii.b. Agglutinogens
Phase I strains of B. pertussis produce one or more heat-labile 
agglutinogens (AGG). These surface components have been shown to be 
involved in the production of agglutinins, antibodies which can cause 
bacterial cell agglutination. AGG-1 is found in all strains of 
B, pertussis, whilst agglutinogens 2-6 may be present in various 
combinations. Preston et al. (1982) suggested that there are three 
major agglutinogens (1, 2 and 3), while 4, 5 and 6 are minor. The
variable combinations of agglutinogens differentiate the main 
B. pertussis serotypes.
The fimbrial agglutinogens (2 and 3) of B, pertussis are possible
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candidates for the initial attachment of the bacteria to the ciliated 
epithelial cells of the respiratory tract during the disease process, 
thus enabling the organism to resist the normal host-clearance 
mechanisms (Beachley, 1981). Gorrlnge et al. (1985) showed that 
monoclonal antibodies to agglutinogens 2 and 3 inhibit the binding of 
B. pertussis to Vero cells in a serotype-specific manner. In addition, 
mice immunised with purified fimbriae are protected against subsequent 
intranasal challenge with virulent B. pertussis (Robinson et al., 
1985b; Zhang et al., 1985). However, Tuomanen and Weiss (1985) have 
shown that non-fimbrlate B. pertussis adhere to ciliated human cells, 
and Tuomanen (1988) has suggested that there is little evidence for 
the role of agglutinogens as adhesins to ciliated cells in humans.
The structural subunits of the serotype 2 and 3 fimbriae Cfim 2 
and fim 3 respectively) have been cloned and sequenced (Livey et al., 
1987; Mooi et al., 1990), Synthetic oligonucleotides derived from 
amino-acid sequences of B. pertussis fimbrial subunits have been used 
to identify clones in a B. pertussis genomic library (Pedroni et al., 
1988). One such clone contains a gene which has been called fim X, and 
shares homology with, but is not identical to, the genes coding'for 
fimbrial agglutinogens 2 and 3.
Charles et al. (1989) have cloned and sequenced the gene encoding 
P.69, a 69-kilodalton non-fimbrial outer-membrane protein which has 
been Identified as an agglutinogen of B. pertussis (Brennan et al.,
1988).
l.iii.c. Filamentous haemagglutlnin
B. pertussis produces two distinct haemagglutlnins, pertussis 
toxin and filamentous haemagglutlnin (FHA) (Aral and Sato, 1976), both
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of which are secreted into the culture medium during growth (Aral and 
Munoz, 1979). Polyclonal and monoclonal antibodies against both 
haemagglutlnins have been shown to confer passive protection against
intranasal challenge in mice (Sato et al. , 1981; Munoz et al. , 1981),
suggesting a role for these factors in pathogenesis. Tuomanen et ai. 
(1985) have also found that transposon mutants lacking FHA or PT 
[BP353 and BP357 respectively - see Section l.vili.d.] show decreased 
adherence to rabbit and human ciliated cells in an in vitro assay
(Tuomanen and Weiss, 1985). However, Weiss et al. (1984) have shown
that mutant BP353 (FHA“) causes a lethal pulmonary infection in an 
infant mouse model, with virulence not significantly reduced from that 
of the wild-type.
FHA appears to be a non-fimbrial protein (Ashworth et ai., 1982), 
with a molecular mass of 210-220kD (Irons et ai., 1983), which forms 
filamentous aggregates 2nm in diameter and 40-100nm long. Brown and 
Parker (1987) have cloned and expressed the gene for FHA in E. coli, 
and Reiman et ai. (1989) have sequenced the FHA structural gene (fhaB) 
which lies adjacent to the bvg locus C see Section l.vi.d. ]. the 
nucleotide sequence of fhaB has suggested that co- or post- 
translational processing may play a role in FHA synthesis,
l.iii.d. Heat-labile toxin
Bordetella species produce a heat-labile, dermonecrotic toxin 
(HLT). HLT causes necrotic lesions when injected subcutaneously into 
mice at low doses (Livey and Wardlaw, 1984), but can be inactivated by 
heating at 56'C for 5 minutes. The toxin has a constrictive effect on 
vascular smooth muscle and may cause inflammation of the respiratory 
tract mucosa during the disease process (Nakase and Endoh, 1988).
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1.111.e. LIpopolysaccharlde endotoxin
B. pertussis endotoxin is composed of two distinct llpopoly- 
saccharlde types, LPS-I and LPS-II (Le Dur et al,, 1980). The 
lipopolysaccharldes of B, pertussis have alternatively been called 
lipoollgosaccharldes (LOS) because they do not contain the long-chaln 
polysaccharide characteristic of the LPS of enteric organisms (Li et 
al., 1988). B. pertussis LPS, in common with LPS from other bacteria, 
is heat-stable, antigenic, pyrogenlc and toxic. However, a definite 
role for endotoxin in pertussis pathogenesis has not yet been 
assigned.
1.111.f. Pertussis toxin
Irons and Gorrlnge (1988) have stated the widely held view that 
"pertussis toxin (PT) is probably the major contributor to the 
pathogenesis of pertussis", although the exact role of PT in the 
virulence of B, pertussis is not known. PT has been the subject of 
numerous reviews including Wardlaw and Parton, (1983); Sekura et al. 
(1985); Ui, (1988); Furman et al. (1988); and Munoz, (1988). The toxin 
has alternatively been known as lymphocytosis promoting factor (LPF), 
histamine-sensitising factor (HSF), islets-activatIng protein XIAP) 
(Yajima et al., 1978a,b), and pertussigen (Munoz and Bergman, 1977), 
giving some indication of its wide range of biological activities.
Pertussis toxin is a hexameric protein composed of five different 
subunits, the genes of which are arranged in an operon (Locht and 
Keith, 1986; Nicosia et al. , 1986). An A-B subunit structure has been
proposed for the toxin, the A subunit being the active protomer, the B 
subunit the binding oligomer (Tamura et al. , 1982). The A subunit is
active in ADP-ribosylation of a guanine nucleotide-binding protein
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(Oi), resulting in loss of inhibition of adenylate cyclase in target 
cells (Katada and Ui, 1982a.b.),
Ui (1988) has classified the biological activities of PT, with 
respect to underlying mechanisms of action, by susceptibility to 
acetamidination of lysine residues. 'Class 1* activities are not 
impaired by acetamidination and include ADP-rlbosylatlon of G- 
proteins, potentiation of adenylate cyclase and stimulation of insulin 
secretion. The acetamldinated toxin being as effective as the native 
toxin in 'Class 1' activities suggests that no free amino groups are 
required for the binding of the B-ollgomer to the target cell surface 
and translocation of the toxin into the cell. 'Class 2' activities, 
including lymphocytosis, histamine-sensitisation, mltogenicity and 
adjuvanticity, are, however, abolished by acetamidination. During 
'Class 2' activities the B-ollgomer has been suggested to bind to 
cells ' divalently', using the amino groups of lysine residues which 
are modified during acetamidination.
The pertussis toxin genes have been cloned (Locht et ai., 1986; 
Nicosia et ai., 1986), sequenced and the amino-acid sequences of the 
individual subunits deduced (Locht and Keith, 1986). Additionally, PT 
subunits have been subcloned and expressed in Escherichia coli, both 
as fusion proteins and as native proteins (Locht et ai., 1987; 
Burnette et ai. , 1988). Recently, Pizza et ai, (1989) have constructed
an Inactive toxin by site-directed mutagenesis. The replacement of key 
amino acids in the enzymatically active SI subunit allowed the 
production of a non-toxic and immunogenic molecule which protected 
mice from intracerebral challenge with virulent B, pertussis.
The PT genes present in B. bronchiseptica and B. parapertussis
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display a high (over 96%) degree of nucleotide sequence homology to 
those in B. pertussis, although neither species expresses the genes, 
probably due to multiple mutations in the promoter region (Marchitto 
et al., 1987),
1.111.g. Tracheal cytotoxin
Tracheal cytotoxin (TCT) is a recently discovered toxin of 
B. pertussis, which has been shown to have cytopathic effects on cells 
of the respiratory epithelium of hamsters (Goldman and Herwaldt, 
1985). Since ciliary activity is the normal clearance mechanism in the 
respiratory tract, destruction of ciliated cells allows accumulation 
of debris, and leaves coughing as the only means of clearing the 
airways. All bordetellae produce TCT, and Goldman (1988) has suggested 
that "the complete conservation of this virulence determinant provides 
strong evolutionary support for its central and essential role in the 
pathogenesis of Bordetella infections".
Goldman (1988) has proposed that TCT derives from the enzymatic 
cleavage of peptidoglycan. A similar peptidoglycan-derived toxin is 
produced by the pathogen Neisseria gonorrhoeae CMelly et al., 1984),
suggesting that TCT may be a virulence determinant common among
mucosal pathogens.
1.111.h. Virulence factors and pathogenicity
The virulence factors produced by B. pertussis have so far been 
reviewed individually, however, during the disease process th'ese
factors presumably contribute synergistically to produce the
'classical stages' of pertussis. A possible sequence of events, both 
for host and parasite, is shown in Fig. 3.
15
Fig. 3 Virulence factors and pathogenesis
A diagrammatic representation of B. pertussis virulence 
factors and their contribution to pertussis pathogenicity and 
immunity. Events affecting both host and parasite are shown. 
Rearranged from Wardlaw and Parton (1988).
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1.Iv Pertussis Vaccines
The introduction of pertussis vaccines into widespread use in the 
UK during the 1950s caused a marked reduction in the incidence of this 
previously common disease. Present day control of whooping cough still 
relies on vaccine prophylaxis. The vaccines currently used in the UK 
are biologically complex suspensions of killed, whole cells of 
B. pertussis with representative serotypes. Inoculation with such 
vaccines may involve some risk, including neurological illness, 
encephalopathy and death CKulenkampff et al., 1974; Manclark and
Cowell, 1984; Ross, 1988). Such reactions have been the cause of much
public concern over the past decade, and have made the production of a
defined component or acellular vaccine a high priority (Robinson ef 
al, , 1985a).
The high protective efficacy (Griffiths, 1988), low toxicity and 
relatively low cost of the current whole-cell vaccine does make the 
Introduction of a demonstrably improved vaccine difficult. However, it 
has been suggested that children inoculated with the whole-cell 
vaccine may act as asymptomatic carriers of the disease, since the 
vaccine may protect against disease but not colonisation (Fine' and 
Clarkson, 1982). An acellular vaccine could possibly be designed to 
protect against both infection and disease.
Robinson et al. (1985a) proposed that multicomponent vaccines 
should include filamentous haemagglutlnin, because of its low toxicity 
and good protective activity against animal infections (Munoz et al, ,
1981); pertussis toxoid (PTd) (Sato and Sato, 1984); and all three 
major serotypes of agglutinogens. Further studies are required on the 
role in the disease process and Immunogenicity of both heat-labile
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toxin and tracheal cytotoxin before they may be considered as vaccine 
components, Outer-membrane proteins (OMP) have been recognised as 
playing an Important role in pathogenesis in a number of Gram-negative 
bacteria (Levine et al. , 1983), and the biological activities of these
components, including the 69kD protein, require further assessment. 
Weiss et al. (1984) have shown that mutants deficient in adenylate 
cyclase / haemolysin are avirulent in the Infant mouse respiratory 
infection model and, if proven to be protective, these components 
should be considered for Inclusion in any new vaccine.
Defined acellular vaccines have been in use in Japan since 1981 
and have been given mainly to two-year-old children. The antigenic 
composition of these vaccines is either FHA: PTd: AGG-2 in the ratio 
90: 10: 1, or FHA: PTd in the ratio 1: 1. This latter type of vaccine has 
also recently been used in Swedish field trials in six-month-old 
infants. Mailings (1986) compared the acellular vaccine with the 
whole-cell vaccine and found it less reactogenic and able to elicit 
good antibody responses to PT. The introduction of such vaccines in 
Japan has resulted in a decline in the incidence of pertussis (Kimura 
and Hikino, 1985), although results from the Swedish field thials 
(Mailings et al. , 1988) have suggested that the acellular vaccine has 
lower protective efficacy than a whole-cell vaccine. However, 
acellular vaccines have proved to be less toxic, less pyrogenlc and 
have been shown to cause fewer local reactions upon injection. Such 
favourable information has stimulated further studies. Robinson and 
Ashworth (1988) have documented the production of a vaccine, 
consisting of equal amounts of separately purified PTd, FHA and 
agglutinogens 2 and 3, to be used in British field trials.
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The preliminary testing of the efficacy of protective antigens 
(or antibodies) for use in human vaccines still relies on animal 
models, which are considered in the next section,
1.V Experimental Infections in Animals
The respiratory tract of a variety of animals can be colonised by 
B. pertussis. However, identification of a relevant animal model for 
pertussis has proved difficult. Only primates, when challenged
intranasally (in), have been reported to develop the characteristic 
cough and mucus production indicative of human pertussis (Weiss and 
Hewlett, 1986). Marmosets do not develop the paroxysmal cough, but 
show the presence of catarrh and nasopharyngeal colonisation by
B. pertussis. Currently, expense and lack of availability prohibits the 
widespread use of primate models.
Young mice, inoculated ln_, are susceptible to colonisation with 
B. pertussis and share a similar course of infection to the human 
disease (Pittman et al., 1980), as well as exhibiting patho­
physiological changes including leukocytosis, histamine sensitisation, 
hypoglycaemia and hyperinsulinaemia. This model has proved valuable
for studies of pathophysiology and immunity in human pertussis and
\
will find continued use in the evaluation of protective activity of
B. pertussis antigens and antibodies (Robinson e£ al., 1985b).
Studies with mice showed the intracerebral (ic) mouse protection 
test to correlate well with the efficacy of the whole-cell vaccines in 
children (Standfast, 1958). This mouse-braln model is increasingly 
recognised as being Inadequate since studies with purified antigens 
(for use in acellular vaccines) have shown only pertussis toxin to be
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protective ic_ (Munoz et al. , 1981). However, Sato and Sato (1988)
suggest for the Japanese acellular vaccine that "while It is difficult 
to justify the ic-challenge method .... there is currently no other 
more suitable or correct method as a national control test for 
protective potency".
1.vl Antigenic Variation In B. pertussis
B. pertussis regulates the production of toxins and other 
virulence factors associated with its ability to cause disease in 
three distinct ways [for recent reviews see Robinson et al, , 1986;
Coote and Brownlie, 19883. 
l.vi.a. Serotvpe variation
B. pertussis isolates have been shown to display heterogeneity in 
serotype. Agglutinogen 1 is always present in phase I isolates, whilst 
the serotype 2 and 3 antigens may be lost or regained independently. 
This phenomenon has been noted in the laboratory (Stanbridge and 
Preston, 1974), in experimental animals (Preston et al., 1980), and in
the child (Preston and Stanbridge, 1972). There is clearly a 
substantial advantage for pathogens in being able to alter' the 
antigenic stimulus which they present to the host, thus avoiding the 
defences of the immune system and enabling repeated or prolonged 
infections.
The molecular mechanisms of relatively rapid changes in serotype 
have been studied in other pathogens including E. coli (Freitag et al. , 
1985), Neisseria gonorrhoeae (Meyer et al., 1984), and Salmonella
typhimurium. In the latter there is a reversible switch involving an 
invertible region of DNA (Zeig and Simon, 1980). In N, gonorrhoeae
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phase variation of fimbrial antigens Involves a cassette-type 
mechanism of DNA rearrangement whereby silent copies of genes encoding 
pilus antigens are moved into expression sites (Meyer et al. , 1982).
Recent research Indicates that serotype variation in B. pertussis may 
be due to single nucleotide insertion or deletion mutations in the 
regulatory regions upstream of agglutinogen subunit genes (Willems et 
al. , 1990).
1.vl.b. Antigenic modulation
Antigenic modulation was first described in B. pertussis by Lacey 
(1960) as a freely reversible antigenic transition caused by changes 
in the bacterial growth environment. Growth on NaCl-containing media 
produced the virulent, or X-mode phenotype, whereas growth on MgSO*- 
contalning media, or on Bordet-Gengou agar at 25*C, produced the 
avirulent, or C-mode phenotype. Pusztai and Jo6 (1967) also observed 
antigenic modulation, induced by increasing the concentration of the 
growth factor, nicotinic acid, in the medium. However, Wardlaw et al. 
(1976) showed that increasing the nicotinamide concentration (an 
alternative growth factor to nicotinic acid) does not similarly Induce 
modulation.
During antigenic modulation several virulence factors and surface 
properties of B. pertussis are lost. Including PT, X-mode specific 
polypeptides (Parton and Wardlaw, 1975; Wardlaw et al. , 1976),
agglutinogens (McPheat et al. , 1983), AC (Parton and Durham, 1978),
HLT (Livey et al., 1978), HLY (Lacey, 1960), cytochrome d629 (Ezzell 
et al., 1981), adhesion (Gorrlnge et al., 1985), hydrophobicity
(Robinson et al., 1983) and uptake of Congo red dye (Parton, 1988).
The rates of conversion of X-mode to C-mode have been studied in
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both batch and continuous culture. In modulation caused by high levels 
of MgSOa, Idlgbe et al. <1981) suggested the selective destruction of
virulence factors. However, Robinson e£ al. (1983) and Brownlie et
al. (1985a) found no inactivation of virulence factors , but that 
further synthesis was repressed. During nicotinic acid-induced 
modulation in a chemostat, Robinson et al. (1983) showed the loss of 
PT and hydrophobicity to be quicker than the theoretical washout rate, 
again suggesting destruction of X-mode characteristics.
Parton and Durham (1978) and Hewlett et al. (1979) suggested that 
cAMP, the product of adenylate cyclase, could play a role in the 
control of expression of virulence factors in B. pertussis. However, 
Brownlie e£ al. (1985b) indicated that expression of adenylate cyclase 
is influenced by the same control mechanisms that act on other 
virulence factors during modulation. Moreover, transposon insertion 
mutants lacking adenylate cyclase produce normal levels of other 
virulence factors (Weiss e£ al. , 1983). Therefore a regulatory role
for AC in antigenic modulation is unlikely, 
l.vi.c. Phase variation
Leslie and Gardner (1931) first described phase variation in 
B. pertussis as the loss of virulence associated with laboratory 
passage of the bacterium. Four antlgenically distinct stages were 
noted, phases I and II being pathogenic, phases III and IV being 
relatively non-virulent. The phase I / phase IV classification system 
is still in use to denote the extremes of phase types. Lawson (1939) 
proposed additional intermediate stages, dependent on strain and 
environmental conditions.
There is still no definitive description of the process of phase
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variation, although Parker (1976) introduced the terms 'fresh 
isolate', 'intermediate strain*, and 'degraded strain' for the 
process, while Weiss and Falkow (1984) have introduced the more 
descriptive designations, 'virulent phase' and 'avirulent phase', as 
concise terms for the potential of the bacterium to cause disease when 
expressing all of the virulence-associated properties. Phase 
transition appears not to be merely an in vitro artifact since 
avirulent organisms can be isolated from patients in the later stages 
of infection (Kasuga et ai., 1954). Weiss and Falkow (1984) proposed 
that avirulent B. pertussis variants might act as a carrier state. 
Organisms in such a state could increase their survival capacity by 
switching off an array of factors useful only in vivo.
Phase variation involves the loss of the same virulence- 
associated factors as antigenic modulation, but not in the same freely 
reversible manner. Avirulent variants have an increased resistance to 
certain antibiotics (Bannatyne and Cheung, 1984), and fatty acids
(Peppier and Schrumpf, 1984). The latter may explain their ability to 
grow on media not supplemented with charcoal, blood, starch or
cyclodextrin. The colony morphology of the phase IV organisms is flat,
rather than the domed colonies of the virulent organism (Peppier,
\
1982). Phase I organisms can also be identified as red (Orb’*') colonies 
on media containing the dye Congo red, whereas variants grow as pale 
(Crb~) colonies (Parton, 1988).
The mechanism of change from virulence to avirulence in
B. pertussis is only now becoming fully understood. Standfast (1951)
and Parker (1976; 1979), proposed that phase variation resulted from a
non-ordered accumulation of point mutations which selected for
— 24 -
variants deficient in virulence properties, but with an enhanced 
capacity to grow in vitro, A multi-step, non-random process for change 
of phase was discussed by Leslie and Gardner (1931). Goldman et al, 
(1984) selected organisms able to grow on defined synthetic media 
known to be unable to sustain growth of phase I organisms, and 
screened the variants for production of HLY, PT and FHA. Only four out 
of a possible eight combinations of these traits were found, 
suggesting phase variation to be an ordered process Involving a multi- 
step disappearance of virulence factors. However, the existence of 
organisms of Intermediate phenotype does not necessarily mean that 
they are Intermediates In the process of phase variation. C,J, 
Duggleby (personal communication) selected for variants on a batch of 
agar unable to sustain the growth of phase I organisms, screening for 
seven virulence-associated factors. These Intermediates showed no 
ordered loss of factors.
Goldman et al. (1987) have suggested that DMA modification may be 
Involved In phase variation, having found variant DMA to be less 
methylated than that In virulent strains and more amenable to 
restriction enzyme digestion. Alternatively, McPheat and McNally 
(1987b) have suggested that DMA rearrangements at the sites of 
repeated DMA sequences may be Involved In the regulation of virulence 
factors, since differences In hybridisation patterns of chromosomal 
DMA digests, probed with repeat sequences, have been shown between 
phase I and phase IV strains.
An alternative mechanism for phase variation Is the single-step, 
reversible change proposed by Weiss and Falkow (1984), for producing 
the fully avlrulent phase variants, Increased tolerance to
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erythromycin was used to select for avlrulent organisms, while 
regained haemolysis was used to screen for the reverse event. Two 
complete cycles of phase variation were demonstrated indicating the 
process to be fully reversible, although reversion appeared to be 
Influenced by environmental factors. The single-step nature of this 
event was further confirmed by the observation that a single Insertion 
of the transposon Tn5 at a specific site In the B. pertussis chromosome 
caused the concomitant loss of LPF, FHA, HLT, HLY and AC In BP347 [see 
Section l.vlll.d. ] (Weiss et al,, 1983).
1. vl. d. Mechanisms of variation
Weiss and Falkow (1984) discussed the finding that a single 
Insertion of the transposon Tn5 Into the B. pertussis genome could co- 
ordinately turn off the expression of virulence factors associated 
with phase I organisms. However, the transposon mutant (BP347) was not 
equivalent to phase IV strains, as It was unable to grow on nutrient 
agar. These authors proposed a model for phase variation, based on the 
avlrulent (Vlr-) transposon mutant BP347, relying upon the existence 
of a Zrans-actlng gene product. The vir gene product was proposed to 
act as a positive Inducer for the virulence-associated genes, alldwing 
co-ordinate expression at multiple loci. The model also provided an 
explanation for the failure to obtain expression of B. pertussis 
virulence factors when fragments of B, pertussis chromosomal DMA were 
cloned In E. coli (Weiss and Falkow, 1983; Brownlie et al. , 1988; C. I.
Duggleby, personal communication). Similar genetic control systems 
have been Identified In Vibrio cbolerae (Mekalanos, 1985), 
Staphylococcus aureus (Recsel et al., 1986) and Pseudomonas aeruginosa 
(Woznlak et al., 1987).
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A potential binding site for the vir gene product was suggested 
to be a set of tandem repeats upstream of the PT operon (Locht and 
Keith, 1986). Gross and Rappuoli (1988) identified the regulatory 
elements Involved In the transcription of the PT operon as including 
the 170bp DNA sequence upstream of the start site of transcription. A 
21bp repeated sequence In this region was proposed to be the binding 
site for the irane-actlvatlng factor(s). However, similar sites have 
not been shown to be present upstream of the adenylate cyclase operon 
(Laolde and Ullmann, 1990), nor the FHA structural gene (Roy et al. ,
1989).
The reversibility of phase change could be accounted for by the 
vir locus or its products being subject to regulation. Foxall et al, 
(1990) have proposed that expression could be controlled by an 
Invertible region of DNA, while Lax (1985) has suggested that phase 
variation could result from a random mutation In the control region, 
followed by selection. Stlbltz et al. (1988) have cloned and mapped 
the vir locus (Fig. 4) from a series of virulent and avlrulent phase 
variants derived from the Tohama III strain, then sequenced this 
region In both types. The 5kb vir locus was Identified juxtaposed to 
the fJia genes and showed no genetic rearrangements between the vir+ 
and the vir- forms of the loci. However, sequence data revealed 
virulent organisms to have a stretch of six cytosine (C) residues In a 
particular region, whereas avlrulent variants had a single insertion 
at this point, giving seven cytosine residues (Fig. 5) (Stlbltz et 
al,, 1989), Hence It appears that one mechanism for phase variation in
B. pertussis strain Tohama Involves a frame-shlft mutation at an 
unstable stretch of nucleotide bases within a central regulatory
-27-
Fig. 4 Restriction map of the bvg-fha region
The restriction map of the genes encoding the trans-
actlvating virulence regulatory proteins ibvgk, B and C> and
filamentous haemagglutinin (.fhaB, fhaA and fheO was rearranged 
from Aricô et al. (1989). The transposon insertion site in mutant 
BP347 is shown in the 2.7kb EcoRI fragment within bvgC.
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Fig. 5 A model for antigenic variation In B. pertussis
Expression of the vir activated genes Cvag) including
ptx, hit, fha, etc., is shown in (a), where the products of
both the vir and mod genes (renamed bvgk and Arlc6 et
al. , 1989) and bvgC (not shown) are required. This
combination of genes does not allow the expression of the
vir repressed genes ivrg). The model for phase variation 
proposed by Stlbltz et al. (1989) is shown in (b), where 
insertion of a single cytosine residue (C) in a string of 
such residues inactivates the vir gene. Knapp and Mekalanos 
(1988) have shown how environmental factors can repress the 
mod gene as seen in antigenic modulation, not allowing 
expression of vag, but allowing expression of vrg (not 
shown).
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locus.
Knapp and Mekalanos (1988) Isolated mutants of B. pertussis which 
constitutively expressed virulence factors in the presence of
modulator stimuli. The gene carrying such mutations was designated mod 
and shown to be distinct from the vir gene (or bvgC), although in 
close physical proximity. The mod gene product has been suggested to 
have sensory functions for the environmental oignais that cause 
antigenic modulation, co-ordinately regulating the vir gene or its 
product (Fig. 5), and as such may be considered to have a function in 
the persistence of B. pertussis in some, as yet unidentified,
alternative environment.
The gene originally designated vir has recently been renamed as 
part of the bvg CBordetella virulence gene) locus. Aricô et al, (1989)
have reported the complete nucleotide sequence of the B. pertussis bvg
region, identifying three open reading frames, bvgA, 6vgB and bvgC. 
The deduced protein products of hvgC and bvgA share homology with a 
family of bacterial signal-transducing proteins and have been 
suggested to correspond to the vir and mod genes respectively [see 
below!.
B. bronchiseptica EcoRI-digested DNA has been shown to have a
\
similar hybridisation pattern to B. pertussis EcoRI-digested DNA when 
probed with the cloned bvg locus on pRMB2 (McGillivray et al. , 1989)
[see Section l.ix.!. Additionally, a derivative of pRMB2, pDMl, has 
been observed to complement avlrulent phase variants of 
B. bronchiseptica to restored expression of virulence determinants, 
Monack et al, (1989) have recently reported that phase variants of 
B. bronchiseptica arise by spontaneous deletions (of 50 - 500bp) in the
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bvg locus. The conservation of the bvg locus in both B. bronchiseptica 
and B. pertussis^ suggests that spontaneous deletions may be an 
alternative mechanism for phase variation in both strains, 
l.vi.e Bacterial signal-transducing proteins
Regulatory proteins have been identified in numerous bacteria; 
such regulatory proteins, which are members of two-component sensory 
transduction systems, consist of a sensory (transmitter) protein and a 
regulatory (receiver) protein (Ronson et al. , 1987). The sensory
component, usually a trans-membrane protein with cytoplasmic and 
extracytoplasmic domains, detects certain environmental stimuli and 
relays the information to the regulatory component, by phosphorylation 
of the receiver, which in turn regulates gene expression by the 
phosphorylated protein binding to specific DNA sites. The transmitter 
and receiver modules are conserved in all signal-transducing proteins, 
while the sensor and regulator modules vary according to the stimuli 
they respond to and the DNA structure with which they interact. Such 
systems have been found which respond to osraolarity in E. coll ienvZ / 
ompR genes), and control virulence in Agrobacierlum tumefaciens (virA 
/ virQ genes) and Vibrio choleras (^o Æ ). The toxR system has been 
proposed to be a one-component analogue of the two-component systems 
(Miller et al., 1987), Gross et al, (1989b) have classified the 
proteins belonging to these systems on the basis of their sequence 
homology.
Aricô et al, (1989) have proposed a model for the three-component 
system of signal-transducing proteins in B, pertussis. Both BvgB and 
the N-terminal portion of BvgC are located in the periplasm where 
environmental signals are recognised and transduced to the cytoplasmic
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transmitter module of BvgC. The receiver portion of BvgA is then 
activated, which in turn allows the regulatory module of BvgA to act 
as a typical transcriptional activator. Additionally, BvgC contains a 
receiver domain fused to the C-terminal part of the transmitter 
module, the role of which is unclear but may possibly be involved with 
DNA binding, or the transmission of other signals which affect the 
activity of BvgA.
l.vii Genetic Transfer In B. pertussis
Branefors (1964) first demonstrated transformation in B, pertussis 
by transferring streptomycin resistance to a sensitive host. Since 
then Weiss and Falkow (1982) have transformed Bordetella species with 
plasmids using cold-shock or freeze-thaw procedures, but only at low 
frequencies, and Lax (1987) has shown improved transformation of the 
bordetellae, obtaining lO'* transformants per microgram of plasmid DNA.
Broad-host-range plasmids, from incompatibility (Inc) groups P 
and W, have been introduced into B. pertussis by conjugation (Weiss and 
Falkow, 1982). Plasmids with a ColEl replicon along with IncQ group 
plasmids were, however, found not to be maintained in B. pertussis.
Based on this Information Weiss and Falkow (1983) used the broad-host-
\
range transfer (tra) genes of an IncP plasmid and the narrow-host- 
range replication genes of ColEl to construct a 'suicide' vector 
(pUW964) for use in transposon mutagenesis of B. pertussis [see Section
l.viii.b.]. Smith et al. (1986) also showed the transfer of various 
IncP group plasmids into B. pertussis and used the transconjugants for 
chromosome mobilisation studies.
Electroporation, the introduction of DNA into cells using a high
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voltage pulse, has recently been demonstrated with B. pertussis CZealey 
et al, , 1988).
i.vill Transposon Mutagenesis
The mutagenic properties of transposons have provided a 
sophisticated technique to investigate the structure and function of 
bacterial genes. In contrast to classical chemical mutagenesis, single 
insertions of transposons can be obtained at a large number of sites 
throughout the bacterial chromosome, causing total inactivation of 
target genes and linking these with the phenotype of the transposon. 
Thus, inserted transposons can provide a genetic marker for the 
identification of their insertion sites, and as such can be used to 
define the limits of a gene. Cloning of interrupted genes utilizing 
the marker genes carried by the transposon permits the screening of 
gene libraries and identification of wild-type genes. For reviews see 
Simon (1989) and Duggleby at al. (1990).
1.viii.a. Transposable genetic elements
Transposable elements are a family of mobile genetic entities 
able to promote their own movement to new genomic locations.
Transposition is independent of host cell recombination systems and
\
does not require extensive areas of DNA homology (Kleckner, 1981).
The smallest transposable elements are the insertion sequences 
(or IS elements) which encode only transposition functions. In 
addition to being found as independent genetic entities, the IS 
elements are also found in the inverted or direct repeated termini of 
composite transposable elements (transposons) (Calos and Miller, 
1980).
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Transposon Tn5 has been used extensively for mutagenesis and has 
many advantageous properties (Berg and Berg, 1983). Initially isolated 
from Klebsiella pneumoniae (Berg et ai., 1975), Tn5 has been 
introduced Into many bacterial species and shown to have a high 
transposition frequency (10"= - 10~® per generation) (Berg and Berg, 
1983), little insertional specificity and low excision frequency (Berg 
et al. , 1980). The transposon is composed of inverted repeats of IS50
(termed 1S5CL and IS50R) encompassing resistance genes to the 
aminoglycoside antibiotics kanamycin, neomycin and streptomycin (which 
is expressed only in certain bacteria), and to the anti-cancer drug 
bleomycin (Fig. 6). The IS elements in Tn5 are independently mobile 
(Berg ei aJ, , 1982), IS50R encoding the functional transposase gene
(Rothstein et al. , 1980). During Tn5 mutagenesis experiments,
independent 1S50 transposition events have been noted in Pseudomonas 
solanacearum (Boucher et al. , 1985) and Erwinia carotovora (Zink et
al. , 1984).
Insertions of Tn5 usually have polar effects, In opérons the 
transcription of genes distal to the insertion site is interrupted. 
However, occasionally insertions in opérons can give rise to a low 
level of constitutive expression of distal genes, due to a promoter 
present near the end of IS50R (Berg et al., 1980).
A variety of Tn5 derivatives have been constructed which offer 
specialised properties. Numerous derivatives carrying alternative 
antibiotic resistance genes are available, including Tn-Ap 
(ampicillin), Tn5-Cm (chloramphenicol) and Tn5-TCl (tetracycline) 
(Sasakawa and Yoshikawa, 1987). An assortment of fusion elements have 
also been constructed to monitor gene expression, or to produce
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Fig. 6 Restriction map of transposon Tn5
Tn5 has been well-characterised physically (Jorgensen 
et al, , 1979; Auerswald ei al, , 1981; Beck et al. , 1982;
Mazodier et al. , 1985). The central antibiotic resistance
genes are flanked by inverted repeats of the insertion 
sequence IS50 (IS5CL and ISS'OR). The promoter (P), for the 
neomycin phosphotransferase gene (which confers resistance 
to kanamycin and neomycin) and the genes encoding resistance 
to bleomycin and streptomycin, is present on the internal 
end of IS50L. A second promoter (?) is present on the 
external end of IS50R and may be the cause of low level 
constitutive expression of some transposon-interrupted 
genes.
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chimaeric proteins eg. TnS-lac (a promoter probe utilizing lacZ)
(Kroos and Kaiser, 1984), and ln5-phok (which creates gene fusions 
with phok and hence can be used to detect protein export) (Manoil and 
Beckwith, 1985).
1.viii,b. Transposon delivery vectors
Transposon mutagenesis requires movement of the transposon from 
the delivery vector, followed by its stable insertion into the host
genome, Selective pressure against the vector, and for the transposon, 
allows for the phenotype of the transposon eg. drug-resistance, to be 
obtained by the recipient only after a transposition event. Many
specialised vectors are available for introducing transposons into
recipient bacterial species, but many have only a limited range of
use.
One strategy for the production of 'suicide' vectors has been the
use of chimaeric plasmids comprising broad-host-range transfer genes
and narrow-host-range replication functions eg. pUW964 (ColEl
replication origin and IncP conjugation genes: Weiss et aJ. , 1983),
and pGS9 (pl5A replicon and IncN conjugation genes: Selvaraj and
Iyer, 1983), Boulnois et al. (1985) based the vector pLG221 on the
narrow-host-range Index plasmid ColIb-P9drd-l, a mutant which
\
constitutively expresses (by derepression) conjugation functions. 
Vectors showing instability outside of E. coll due to the insertion of 
phage Mu DNA have been characterised eg. pJB4JI (Beringer et al. ,
1978). Meade et al. (1982) have, however, shown that in some species 
Mu can co-transpose with Tn5, with the potential to cause genetic 
rearrangements at the Insertion site. Both temperature-sensitive 
mutants of transmissible plasmids (Jacob et al. , 1963; Laird and
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Young, 1980) and bacteriophages (Berg et al. , 1975; Kleckner et al. ,
1977) have also been utilized as transposon delivery vehicles.
Simon et al. (1983) described a novel transposon delivery system 
comprising narrow-host-range plasmids containing the specific IncP- 
type recognition site for mobilisation imob site) within specific 
donor strains having the IncP RP4 transfer genes integrated into their 
chromosome. These plasmids are therefore mobilisable into bacteria 
which are normally receptive to broad-host-range IncP plasmids,
l.viii.c. Transposon mutagenesis in pathogenic bacteria
Kleckner et al. (1977) first used transposon mutagenesis, 
inserting Tn5 or TniO, to generate auxotrophs of E, coll and 
S. typhlmurlum. Since then a plethora of experiments have been 
conducted, many on bacterial pathogens. Insertion mutations in 
bacterial pathogens may allow the identification of genes specifying 
virulence determinants. Such genes can be cloned and expressed in 
E. coll, and the purified product of the cloned gene can be studied in 
animal models, or modified to identify important structural 
properties. Additionally, mutants with phenotypes altered from the 
wild-type parent strain can be evaluated in animal models and' the 
contribution of particular virulence factors to the disease process 
examined (Weiss and Falkow, 1983).
Among the pathogens investigated, Leung and Stevenson (1988) have 
reported Tn5-induced protease-deficient strains of Aeromonas 
hydrophlla, which have reduced virulence in fish. In mammalian 
pathogens, transposon mutagenesis has been reported in Brucella 
abortus (Smith and Heffron, 1987), Legionella pneumophila (Keen et 
al. , 1985) and the 140-megadalton Invasion plasmid of Shigella
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flexneri (Sasakawa et al., 1986). Tn5 mutagenesis has been used in 
Bordetella avium, the causative agent of coryza in turkey poults, to 
identify non-haemagglutinating mutants (Leyh et al., 1988), but of the
bordetellae, the human pathogen B. pertussis has undoubtedly undergone 
the most extensive Investigation by transposon insertion mutagenesis.
1.viii.d. Transposon mutagenesis of B. pertussis
Weiss et al. (1983) and Robinson et al. (1986) have reported Tn5 
mutagenesis of B. pertussis and the identification of mutants unable to 
express virulence factors (Table 1). Mapping studies around the 
transposon insertion sites suggested no clustering of the virulence 
factors around specific areas of the genome, although a mutant 
deficient in both adenylate cyclase and haemolytic activity suggested 
that the genes expressing these functions were linked on an operon. 
Weiss et al. (1984) used intranasal infection of infant mice to test 
the virulence of TnS'-induced mutants (Table 2), The avlrulent 
transposon mutant BP347 was utilized by Stlbltz et al. (1988) to 
identify the interrupted bvg locus and to clone the wild-type genes 
into cosraid pUW21-26, Tn5 mutagenesis in E. coll was then used to 
define the limits of the locus.
Knapp and Mekalanos (1988) used UnS-phok gene fusions to define 
two sets of genes whose expression is either activated ivag loci) or 
repressed (vrg' loci) by modulation signals. Both vag and vrg loci were 
shown to be regulated by the bvg locus gene products, since insertion 
mutations in bvg lead to repression of vag gene fusions and 
derepression of vrg gene fusions.
Weiss et al. (1989) introduced Tn5-iac insertions into 
B. pertussis vir-regulated genes. Such insertions were identified by
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Table i
Transposon mutants of B. pertussis
Genes 
mutated 
/f used
Transposon No. of 
mut ant s
Strain Identification
No.
Referenci
fha Tn5 1 Tohama BP353 1
Tn5 4 Wellcome 28 2
hly Tn5 1 Tohama BP349 1
Tn5 Wellcome 28 2
cyaA In 5 1 Tohama BP348 1
Tn5 1 Wellcome 28 2
ptx Tn5  ^+ / — Tohama BP357 1
Tn5 2 Wellcome 28 2
flnQ Tn5 6 Wellcome 28 2
vir Tn5 1 Tohama BP347 1
vag Tn5-phoA 8 18-323 3 '
vrg Tn5-phoA 5 18-323
\
3
Reduced levels.
Ref erences
1. Weiss et al. (1983).
2. Robinson et al. (1986).
3. Knapp and Mekalanos, (1988).
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Mutant
Table 2
Virulence of B. pertussis Tn5 mutants 
Phenotypic characteristics LDeo in suckling mice 
(cfu/mouse)
BP338 Cwt ) Adc+ , Hly-. Fha-, Ptx-, Hlt- 2x10=
BP347 Adc“, Hly-, Fha-, Ptx-, Hlt- >3x107
BP357 Adc+,, Hly-, Fha-, Ptx-/-, Hlt- 5x10*
BP353 AdcT, Hly-, Fha-, Ptx-, Hlt- 8x10=
BP349 Adc+,, Hly-, Fha-, Ptx-, Hlt- 4x10*
BP348 Adc-, Hly- Fha-, Ptx-, Hlt- >3x107
Taken f rom Welss et al. (1984).
- 43
expression of p-galactosidase during X-mode conditions, followed by 
loss of expression in C-mode growth conditions. Of fourteen mutants 
only six had insertions in known vir-regulated genes.
1. ix Cloning of B. pertussis Genes
Most experiments involving cloning of B. pertussis DNA have been
performed on the virulence-related genes eg, ptx, cyaA, fim, etc. C see
Section l.iii.3. Sequencing has allowed the deduction of amino-acid 
sequences and the Identification of potential epitopes. For the 
production of new acellular vaccines, the known epitopes of cloned 
genes could be manipulated to provide protective but non-toxic 
components. Cloned genes with increased expression could also prove 
advantageous for vaccine production. However, expression of the 
virulence genes in E. coli has proved difficult because of the 
requirement for the trans-activating virulence control genes (Weiss 
and Falkow, 1983). Brownlie ei al. (1988) identified a plasmid (pRMB2) 
from their gene library which contained the bvg locus. Mapping and 
subcloning of pRMB2 has identified regions of similarity in this clone 
to the map of Stibitz et al. (1988) (Fig. 7) (McGillivray eb al. , 
1989).
Shareck and Cameron (1984) have cloned DNA fragments which code 
for the synthesis of two outer-membrane proteins of 33 and 30kD, while 
Brownlie et al. (1986) have shown expression of the trpE and glnA
genes of B. pertussis in E. coli. More recently, Maskell et al. (1988)
have cloned, sequenced and expressed the aroA gene in E. coli, without 
the requirement of expression vectors.
Stern et al. (1984) have noted the presence of repeated DNA
- 44
Fig. 7 Restriction map of the bvg-fha region on pRMB2
The restriction map of pRMB2 shows a region of 
similarity to the map of Stibitz et al, (1988), along with a 
non-matching region, considered to be a non-contiguous 
fragment (McGillivray et al. , 1989). The central arrow
denotes the joining point of these two fragments. An llkb 
deletion used in the construction of the subclone pDMl is 
also shown.
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sequences In the genomes of many bacteria. A repeat sequence with at 
least 20 copies has been identified in B. pertussis, but shown to be 
absent in B. parapertussis, B. bronchiseptica (McPheat and McNally, 
1987a), and B. avium (McPheat and McNally, 1987b). The sequence has 
been cloned and may find use as a genetic probe for the identification 
of B. pertussis strains. Repeat sequences have also been identified by 
Park et al. (1988) and Alsheikhly and Lôfdahl (1989), the latter being 
present in B. pertussis, B. parapertussis and B. bronchiseptica in more 
than one copy.
- 47 -
Object of Research
The project was directed towards the establishment of the most 
suitable Tn5 delivery system for insertion mutagenesis of B. pertussis, 
Transposon mutants with specific virulence-related phenotypes were to 
be isolated to further our understanding of the different modes of 
regulation of virulence factor production in this pathogen and to 
identify any new genes associated with virulence regulation.
An additional directive of the project was the use of a bank of 
transposon mutants to identify isolates deficient in production of 
single virulence-associated factors and to assess the virulence of 
these strains in animal models. Mutants with relevant properties were 
to be considered for use as vaccines to study protective activity in 
Infant mice.
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MATERIALS AND METHODH
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2. 1 Bacterial Strains and Plasmids
2.1,a. Bordetella pertussis strains
B. pertussis Wellcome 28 strain phase I (serotype 1,2,3) was 
supplied by P. Novotny (Wellcome Laboratories, Beckenham). B> pertussis 
Tohama phase I (serotype 1,2) was obtained from the Centre for Applied 
Microbiology and Research culture collection (PHLS, CAMR, Porton Down, 
Salisbury), as was B. pertussis 134 phase I (serotype 1,3). These 
strains were obtained from A. Robinson (Biologies Division, CAMR).
B. pertussis Tohama 347 (BP347), a transposon-insertion mutant
pleiotropically negative for the expression of virulence-associated 
factors <Vlr~) due to a Tn5 insertion in the irans-act1vating 
virulence regulatory locus vir, was supplied by A. Weiss (Virginia 
Commonwealth University, Richmond, USA). B. pertussis Tohama 348 
(BP348), a non-haemolytIc <Hly~) Tn5-insertion mutant lacking the 
ability to express adenylate cyclase (Adc“), was also supplied by
A. Weiss. These strains were obtained from the Microbiology Department 
culture collection (Glasgow University). B. pertussis 18-323 vaccine 
strain, which was used as the challenge strain in mouse protection 
tests, was also obtained from this source.
B. pertussis L84 phase I Crb“, a spontaneous mutant of strain L84 
phase I unable to bind the dye Congo red (associated with avlrulent 
Vir" strains), was supplied by R.Parton (Glasgow University).
B, pertussis, a Category 2 pathogen according to the 
categorisation scheme of the Advisory Committee on Dangerous Pathogens 
(ACDP), was handled under the appropriate containment conditions 
(ACDP, 1984).
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2, i. b, Escherichia coli strains
E, coli strains used in this study, and their relevant
characteristics, are shown in Table 3.
2.i.c. Plasmids
Plasmids used in this study are shown in Table 4.
2.11 Media
The chemically-defined media of Stainer and Scholte (1971), with 
the growth stimulant heptakis (2,6-0-dimethyl) p-cyclodextrin 
(SS(MePCD)) (Imaizumi et al., 1983), was used for liquid culture of 
B. pertussis and E. coli strains, This cyclodextrin was obtained from 
Teijin Limited (Tokyo, Japan). Growth supplements were added to the 
media prior to use, and 1% ('"/v> casamino acids were added where
minimal conditions were not required (SS(MepCD+CAA)). Cyclodextrin 
solid medium (CSM) or Bordet-Gengou agar (BG) were used for solld-
phase growth of B. pertussis. Nutrient agar CNA) and nutrient broth
(NB) were used for solid- and llquid-phase growth of E. coli strains 
respectively. Bacterial cultures were stored at -20°C in a glycerol- 
based casamino acids solution. [See Appendix 1 - Media preparation].
2. ii.a, Cyclodextrin solid medium for selection of avlrulent mutants
\
CSM for use in the selection of potentially avlrulent transposon 
mutants was prepared using a batch of agar - Difco Bacto No. 726942, 
previously shown to inhibit the growth of phase I organisms.
2. ii. b. Congo red (CR)
Congo red dye (Sigma) for use in differentiation of virulent and 
avlrulent B. pertussis strains, was made up as a 1% (*/^) solution in 
distilled water, filter sterilised and added to CSM to a final
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Table 3 
E. coli strains
Relevant
Strain Characteristics Plasmids Source
E. coli HBlOl Leu-, Pro-, Thi- pRK2013 CAMR culture collection
E. coli HBlOl Leu-, Pro-, Thi- pUW964 A. Weiss*
E, coli HBlOl Leu-, Pro-, Thi- pGS18 V. Iyer*
E. coli 1830 Met-, Pro- pJB4JI J. Beringer*
E. coli WA803 Met-, Thi- pGS9 V. Iyer*
E, coli S17-1 Pro-, Thi- pSUP2021 R. Simon*
Mobilisation strain
RP4-2-Tc: : Mu-Km: : Tn7
Tp*, Sm^.
E. coli C600 Leu-, Thi-, Thr- pLG221 G. Boulnois*
E. coli W3110 pColIb-P9 cfrd CAMR culture collection
E. coli G802 His-, cyaAA854 S, Garges* (A854; Garges 
and Adhya, 1985)
E. coli DHl Thi- pRMB2 R, Brownlie
E. coli JM83 Pro- pDMl D. McGillivray
E. coli DHl Thi- pRMBll R, Brownlie
^Obtained by C.J. Duggleby
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Table 4
Plasmids
Relevant
Plasmid Size Characteristics Ref erence
pRK2013 48.Okb P-gToup tra genes, ColEl Figurski and
replicon. Mobilisation Helinski (1979)
vector. Km^
pUW964 73.Okb pRK2013ifan: : Tn7xyz\ : Tn5 Weiss eÉ al. (1983)
Tp^, Sp*^ , Km*.
pJB4JI 97.2kb pPHlJI: : Mu; ; Tn5. Hirsch and Beringer
Cm*, Sp*, Km*. (1984)
pGSia 29.5kb N-group tra genes, pl5A Selvaraj and lyer
replicon. TnL Cm*, Ap*. (1983)
pGS9 30. 5kb N-group tra genes, pl5A Selvaraj and lyer
replicon. Tn5. Cm*, Km*. (1983)
pSUP2021 13.2kb pBR325 replicon. Mob+. Tn5. Simon et al. (1983)
Ap*, Cm*, Km*.
pColIb“P9 93.2kb Derepressed I„“group tra genes. Rees et al. (1987)
pLG221 99. Okb ColIbdrd-1 cib\ : Tn5, Km* Chatfield et al.
(1982)
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Table 4 (cont,)
Relevant
Plasmid Size Characteristics Ref erence
pRMB2 47. 7kb pLAFRl derivative containing 
B. pertussis vir locus. Te*.
Brownlie et al, 
(1988)
pDMl 33.6kb Subclone of pRMB2 containing 
vir locus. Te*
McGillivray et al. 
(1989)
pRMBl1 Vector pIC20H containing the 
5. 5kb Clal fragment encoding the 
transcriptional start site of 
the adenylate cyclase operon.
Brownlie (personal 
communication)
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concentration of 0.002%.
2. ii.c. ICR 191
ICR 191 (Polysciences, Inc. , Worrington, PA, USA) (an acridine- 
based compound which induces frameshift mutations; Miller, 1972) was 
made up as a 1mg/ml solution in distilled water and stored in the dark 
at -20'C. This mutagen was added to liquid media immediately prior to 
use, or to solid media up to 20 hours before use (to facilitate 
diffusion into the agar).
2.11,d, IPTG
Isopropyl p-D-thiogalactopyranoside (IPTG) (Sigma) was prepared 
as a 25mg/ml stock solution in distilled water and stored at -20°C. 
Stock solution was diluted in media to give a final concentration of 
40pg/ml.
2. ii. e. X-gal
5-BromO“4“chloro-3-indoyl-p-D-galactopyranoside (X-gal) (Sigma) 
was prepared as a 25mg/ml stock solution in dimethyl formamide and 
stored at -20°C. Stock solution was diluted in media to give a final 
concentration of 40pg/ml.
2.11.f. Antibiotics
Antibiotics were made up in distilled water, the exceptions being 
amphotericin (made up in dimethyl sulphoxide - DMSO), tetracycline 
(made up in ethanol) and trimethoprim (made up in methanol), filter 
sterilised and stored at -20°C.
Final concentration 
Amphotericin (Amph) 25pg/ml
Cephalexin (Ceph) 50pg/ml
Chloramphenicol (Cm) SOpg/ml
-55-
Final concentration
Gentamycin sulphate (Gm) 5pg/ml
Kanamycin sulphate (Km) 50pg/ml
Spectinomycin (Sp) 200pg/iril
Streptomycin (Sm) 200pg/ml
Tetracycline (Tc) 20pg/ml
Trimethoprin <Tp) 50pg/ml
2.ii. g. Sterilisation
All equipment and media required sterile were autoclaved at 120*C 
for 15rains at 15psi. Solutions requiring sterilisation were passed 
through a Millex GV Milllpore 0. 22pm disposable filter unit CMolsheim, 
France).
2.ill Microbiological Techniques
2.ill.a. Filter conjugation
Filter conjugations were performed to introduce Tn5 into 
B, pertussis from a variety of delivery vectors present in E, coli donor 
strains.
B. pertussis recipient strains were grown on CSM at 37*C for 3-4 
days, then transferred to flasks containing 50ml SS(MepCD+CAA). The 
flasks were incubated overnight at 37'C with shaking (lOOrpm). E, coli 
donor strains were streaked onto CSM+Km and Incubated over-night at 
37°C, then used to inoculate flasks containing 50ml SS(MepCD+CAA+Km). 
The flasks were incubated at 37'C, lOOrpm, Optical density readings of 
the donor and recipient bacterial strains were taken every few hours 
until each had reached an ODeAor^w=0- 4. Purity of the strains was 
checked by Gram staining.
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Cell suspensions for conjugation were prepared from each strain 
by diluting cultures of standard optical density, then viable cell 
counts made. The standard suspensions for conjugation were mixed and 
2,5ml filtered through a 2cm diameter nitrocellulose filter (pore size
0.45pm) in a presterilised filter unit. Filters were removed from 
filter units, placed (cells upward) on CSM plates and incubated at 
37°C for 18 hours. Approximately ten matings were performed for each 
different donor strain. A 2ml volume of the B. pertussis standard
suspension for conjugation was filtered (as above) to identify the 
frequency of spontaneous resistance to kanamycin.
The growth on the filters was resuspended in 5 ml SS(MepCD). 
B. pertussis transconjugants containing Tn5 were selected on
SSA(MepCD+Km+Ceph) (resistance to kanamycin selects f or the 
transposon, while minimal media and cephalexin select against the 
auxotrophic B. coli donor strains - Table 3). Final viable counts were 
made for both B. pertussis and E. coli strains. Cells from the
B, pertussis control mating were plated onto CSM+Km.
B. pertussis kanamycin-resistant transconjugants were picked and 
colony-purified three times, then stored at -20°C in a glycerol based 
solution.
\
2,ill.b. Plate conjugation (Smith et al., 1986)
Plate conjugations were performed to increase the yield of
transconjugants during matings to obtain Tn5 mutants unable to bind 
Congo red (Crb“), and to Zrans-complement the Crb“ Tn5 mutants with 
pRMB2 or pDMl.
B. pertussis strains were grown in liquid media for 1-2 days at 
37°C, lOOrpm, then lOOpl of culture was spread on SSA(MepCD+CAA)
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mating plates and incubated for 2 days at 37"C. E.coli donor strains 
(and helper strain HBlOi pRK2013 if required) were grown on 
appropriate antibiotic containing plates overnight at 37°C, then 
transferred to liquid media and incubated overnight at 37”C, lOOrpm.
E. coli strains were diluted 1 in 10 (both donor and helper 
strains) and lOOpl of culture added to the B. pertussis mating plates. 
Cell suspensions were mixed and incubated for 5 hours at 37°C.
Bacteria were resuspended in 1ml SS(MepCD) and 50pl spread on 
selection plates. Tn5 mutants unable to bind Congo red (Crb~) were 
selected for on SSA(MegCD+Km+Ceph+CR). The same selection medium, with 
the addition of tetracycline, was used for complementation studies 
(see below). B. pertussis and E.coli strains were also individually 
spread on selection plates to act as controls. Selection plates were 
incubated for 7-10 days to allow for the growth of single colonies of 
B, pertussis transconjugants on minimal media. Transconjugants were 
colony purified by streaking to single colonies three times, then 
stored as previously.
2.111.c. Complementation studies
During conjugations to show complementation in trans of 'Crb“ 
B, pertussis transposon mutants with the cloned virulence-regulatory 
genes on pRMB2, or pDMl, selection plates comprised 
SSA(MepCD+Km+Ceph+Tc+CR). Colonies showing the Crb^ phenotype were 
restreaked on BG agar with appropriate antibiotics to ascertain regain 
of haemolytic activity.
2.111.d. Antibiotic-resistance screening
B. pertussis kanamycin resistant transconjugants were screened for 
maintenance of the transposon delivery vector by multi-point
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inoculation, from microtitre trays, onto antibiotic containing plates, 
The multipoint inoculator was alcohol flamed to prevent contamination. 
Transconjugants were simultaneously inoculated onto CSM to show growth 
in the absence of antibiotics. Donor and recipient strains were also 
spotted onto both CSM and antibiotic-containing plates as controls,
2.111.e. Modulation studies
B. pertussis strains on CSM+CR, or BG overlay plates, were grown 
at 25 °C to show antigenic modulation. Alternatively, plates were 
prepared containing 20mM MgSO^ (in place of NaCl).
2.111.f. Frameshift mutagenesis
Frameshift mutagenesis experiments were performed on B. pertussis 
Tn5 mutants (where the Crb“ phenotype was not associated with the 
insertion mutation) to identify any spontaneously avlrulent mutants. 
Two methodologies were used: -
i. On solid media.
A central plug of agar was removed from CSM+CR plates and stock 
solution of ICR191 added to the well. Plates were left over night for 
the mutagen to diffuse outwards. As controls B. pertussis Wellcome 28 
(Crb+) and B. pertussis L84 phase I (Crb~) strains were resuspended
from CSM+CR plates, diluted 10"^ and lOOpl spread evenly onto
\
mutagenesis plates. Plates were incubated for 5-6 days to allow growth 
to single colonies. Since ICR191 appeared to react with the dye 
(possibly affecting uptake), colonies were replica plated onto CSM+CR 
and Incubated for a further 5-6 days.
ii. In liquid media (Miller, 1972).
In control experiments B. pertussis Wellcome 28 (Crb^D and B. pertussis 
L84 phase I (Crb“) were mutagenised in foil-wrapped flasks containing
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50ml SS(MePCD+CAA). ICR191 was added to final concentrations of 
between 0, 5fig/ml and 20pg/ml immediately prior to inoculation with 
overnight cultures. Control flasks were left free of mutagen. Flasks 
were incubated with shaking at 37“C and samples removed twice daily 
for 3 days. Samples were diluted, plated onto CSM+CR and incubated for 
7-8 days at 37*C. The ratio of Crb+: Crb“ colonies from each sample
was calculated and plotted against time.
Crb~ transposon mutants were Incubated with 0. 7pg/ml ICR191 for 2 
days. Cultures were diluted and plated onto CSM+CR+Km and any Crb^ 
revertants noted.
2. Iv DNA Techniques
[See Appendix 2 - Buffers and Solutions for DNA Techniques]
2.iv.a. Chromosomal DNA preparation
Cells from confluent growth on one plate of CSM were suspended
in 10ml TE buffer, 2ml lysozyme (20mg/ml) added and cells incubated
at 37*C for 15 minutes. EDTA (4ml of 0. 5M> was added and cells were
left for 5 minutes at room temperature, followed by the addition of
4ml 20% SDS and incubation at 60 “C for 1 hour wit'h
occasional swirling. Lysates were left to cool and then extracted
\
twice with an equal volume of equilibrated phenol/chloroform. After 
separating the phases by centrifugation for 15 minutes at SOOOrpm 
and discarding the organic phase and interface layer, a further 
extraction was carried out. Then, one tenth volume of 5M NaCl was 
added and mixed in by gentle inversions, prior to the addition of 
two volumes of ethanol. After 30 minutes at -20 “C the DNA was 
spooled out, dissolved in 8ml TE buffer, and left overnight at 4'C.
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RNA was removed by adding preboiled (15 minutes) RNase A 
(0.42ml, Img/ml) to the DNA solution and incubated for 2 hours at 
37 "C, After this any remaining protein was removed by adding SOjil 
0. 5M EDTA, 0,25ml 20% SDS, and 0.5ml pronase (Img/ml). After
incubation for 1 hour at 37°C the solution was extracted twice with 
equilibrated phenol/chloroform and once with chloroform (as 
previously). One tenth of the volume of 5M NaCl was added followed 
by two volumes of ethanol at -20*C, prior to respooling the DNA on 
a glass rod. The DNA was dissolved in 4ml TE buffer and dialysed at 
4'C, overnight against four changes of TE, each of 1 litre.
2.iv.b. Large scale plasmid preparation (Hansen and Olsen, 1978)
An E. coli starter culture was incubated at 37'C, lOOrpm, for 6 
hours. Of this, 2ml was used to inoculate 1 litre of L-broth, which 
was grown overnight. Chloramphenicol was added to a final
concentration of 170pg/ml and the culture left shaking vigorously 
for 4-18 hours.
Cells were harvested by centrifugation for 15 minutes 9000g, 
at 4'C. Supernate was removed and the cells resuspended in 2.6ml of 
25% ("/v) sucrose in 0.05M Tris-HCl, pH8. 0, and transferred to h
polypropylene centrifuge tube maintained on ice. Cells were lysed
\
by the addition of 2ml lysozyme (20mg/ml in 0, 25M EDTA, pH8. 0) and 
the tubes kept at 37'C for 5 minutes, with swirling. After this
2. 6ml of 0. 25M EDTA (pH8. 0) was added and the lysate swirled
intermittently on ice for 5 minutes. Brlj./DOC (4ml) solution was 
added rapidly from a 10ml pipette, mixed, then left on ice for 20- 
30 minutes.
Cell debris was pelleted along with the bulk of the
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chromosomal DNA by centrifugation for 45 minutes, 15, OOOg at 4'C. 
The cleared lysate was carefully decanted into a fresh tube and the 
volume measured. Solid caesium chloride (CsCl) was added at the 
rate of 0.95g/ml to the cleared lysate. After this 0. 1ml ethidium 
bromide solution <20mg/ml in dH^O) was added and the solution 
transferred to a labelled Ti50 (Beckman) polyallomer tube. Tubes 
were balanced in pairs to within 50mg, then all the air was 
displaced and the tops heat-sealed. The tubes were transferred to a 
Ti50 rotor and centrifuged at 39, OOOrpm for 36-40 hours, 18'C.
Tubes were carefully removed from the rotor and clamped under 
ultraviolet (uv) illumination. The lower plasmid band was removed 
by puncturing the side of the tube with a syringe needle. Plasmid 
DNA was allowed to drip into a tube, the ethidium bromide removed 
by extraction with isopropanol (equilibrated with a saturated 
solution of CsCl), and the DNA dialysed against three changes (1 
litre each) of TE buffer at 4'C, overnight.
2. iv. c, DNA concentration and purity
DNA concentration and purity were measured spectrophoto- 
metrically by reading the OD^eonr^ and OD^eovim* Pure DNA solutions
have OD^ so/'ateo ratios > 1, 7. Duplex DNA solutions at 50p.g/ml have
\
an OD^eo of approximately 1.
2.iv.d. Precipitation of DNA
One tenth volume of 3M ammonium acetate and 2. 5 volumes of 
cold absolute ethanol were added to the DNA solution and mixed. DNA 
was incubated at -70°C for 15 minutes, then centrifuged at maximum 
speed in a microfuge (10,OOOrpm) for 15 minutes. The supernate was 
carefully removed and the pellet dryed In vacuo. DNA was
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resuspended in TE buffer to the required concentration.
2.iv.e. Restriction enzymes
Restriction enzymes (Table 5) and xlO reaction buffers were 
obtained from BRL, except Hpal (Pharmacia) which was used in the 
presence of the medium salt buffer (Maniatis et al., 1982). 
Digestions normally contained Ipg DNA and l-5units of enzyme in a 
20pl reaction volume, and were incubated overnight. After 
incubation 5pl of loading buffer was added to 20pl of digested DNA, 
centrifuged briefly and loaded onto a gel.
2.iv.f. Lambda Hlndlll markers
For the production of markers 2pg of X DNA (BRL) was added to 
40pl Ix React^M 2 buffer (BRL). The restriction enzyme Hlndlll 
dpi) was added and left to react for 1 hour at 37°C. Restriction 
fragments were used as molecular weight markers either directly on 
gels, or were 3'-end-labelled for use as radioactive markers (see 
below).
2. iv.g. End-labelling of markers (Downing et al., 1979)
Approximately 500ng of a X-Hindlll digest was added to 50pl of 
Ix Core buffer (BRL). After this, lOpl of A solution (containing 
0. ImM each of the deoxyribonucleotide triphosphates dCTP, dGTP and 
dTTP) was added, followed by Ipl of «-"^^P-dATP (Amersham: specific
activity = 3000 Ci/mmol; radioactive concentration = lOmCi/ml). The 
reaction was started by the addition of 1 unit of the large 
(Klenow) fragment of E.coli DNA polymerase (Boehringer Mannheim). 
The mixture was incubated at room temperature for 15 minutes then 
loaded directly onto a gel.
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Table 5
Restriction enzymes
Enzyme Conditions Cleavage site
Reaction buffer Temperature
BamHI REact 3 ™ 37'C 5' -GiGATCC-3'
EcoRI REact 3 ™ 37'C 5' -GlAATTC-3'
HindiII REact 2 ™ 37‘C 5' -AlAGCTT-3'
Hpal Medium salt* 37'C S' -GTTiAAC-3"
Sail REact IQTM 37'C 5' -GlTCGAC-3'
*Maniatls et al. (1982)
REact^M buffers were obtained from BRL
[See Appendix 2 for composition of reaction buffers]
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2.iv.h. Agarose gel electrophoresis
DNA fragments were separated by agarose gel electrophoresis on 
the basis of size (in 1% agarose the relationship between log^o 
size and mobility is approximately linear for DNA fragments between 
7kb and 0.5kb). Plots of log,o molecular weight versus mobility 
using standard DNA fragments were used to determine the size of 
unknown fragments.
Horizontal gel electrophoresis systems (Phamacia) were used 
throughout. Agarose Type II-A Medium EEO (Sigma) was used except in 
the production of restriction fragment length probes (see below). 
Both E buffer and B buffer (Ix or 0. 5x strength) were used. Agarose 
was prepared by boiling in buffer solution and poured when the 
temperature had dropped to around 50'C.
DNA fragments were detected by staining gels with ethidium 
bromide (Ipg/ml) for 20 minutes. The gels were washed in distilled 
water and examined using long-wave uv light to Illuminate the DNA 
bands. Photographs were taken through a red filter, using Polaroid 
Type 667 film.
2.iv. i. Southern blotting
Restriction enzyme digests of B. pertussis chromosomal DNA were
\
transferred to nylon membrane (Hybond-N^^^ Amersham) using a vacuum 
blotting system (LKB 2016 V a c u g e n e ^ " ,  Vacuum Blotting System).
The nylon membrane was dampened with 2xSSC, placed on the 
porous support stand within the area cut away from the plastic mask 
and the gel was cut to a suitable size and laid over the nylon 
membrane, covering the edges of the plastic mask. The gel was 
immobilised by application of the vacuum.
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Depurination solution was pipetted onto the surface of the gel 
and the vacuum stabilised at 40cm H^O. After 4 minutes the solution 
was aspirated off and replaced by dénaturation solution. This was 
replaced after 3 minutes by the neutralisation solution. After 3 
minutes neutralisation, the solution was removed and the gel 
covered to twice its depth in the transfer solution (20xSSC). 
Transfer was allowed to proceed for 50 minutes under a constant 
vacuum.
After transfer of the DNA was complete the filter was washed 
briefly in 2xSSC, blotted between Whatman 3MM filter paper and 
wrapped in Saran Wrap^n (Dow Chemical Co. ). Damp filters were 
examined under uv illumination to show transfer and to fix the DNA, 
then stored at 4’C,
2.iv.j. Hybridisation conditions
Filters were heat-sealed in a plastic bag containing 0. 1ml of 
prehybridisation solution per cm^ membrane [see Appendix 2] and 
incubated for 2-3 hours at 42 °C in a shaking water bath. For 
hybridisation the denatured probe (made by boiling for 5 minutes) 
was added to the prehybridisation solution in the bag, all the ai'r 
bubbles were removed and the bag resealed. Hybridisation was 
allowed to proceed overnight at 42’C.
Filters were washed in 50ml 2xSSC for 15 minutes at 65’C, then 
in 50ml 2xSSC containing 0. 1% ("7^) SDS for 30 minutes at 65°C, and 
finally in 50ml 0. IxSSC for 10 minutes at 65'C, to remove 
unincorporated probe. Filters were not dried completely, to 
facilitate reprobing, but were wrapped damp in Saran Wrap for 
autoradiography.
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2.Iv.k. Preparation of restriction fragment length probes 
CFeinberg and Vogelstein, 1984)
Plasmid DNA was cleaved with the appropriate restriction 
enzyme and the fragments separated by electrophoresis in \% ("7^) 
low-gelling-temperature agarose (using E buffer). After 
electrophoresis, the gel was stained with ethidium bromide and the 
desired band excised under uv illumination. Both Hpal and Hindlll 
restriction fragment probes of Tn5 were prepared from a plasmid 
preparation of pSUP2021 using this technique. Distilled water (3ml 
H^O per Ig of gel) was added to the DNA-containing agarose slice in 
a microfuge tube, which was then placed in boiling water for 7 
minutes to melt the agarose and denature the DNA. Such probes were 
then stored at -20“C. In preparation for subsequent radioactive 
labelling, the gel was reboiled for 5 minutes and stored at 37'C 
for 10-60 minutes until starting the labelling reaction.
2. iv. 1. Random hexanucleotids labelling of probes (Felnberg and 
Vogelstein, 1983)
The labelling reaction was carried out overnight at room 
temperature. The following reagents were added in the stated ordeh:
(1) distilled water (to a total volume of 50pl); (ii) lOpl oligo-
\
labelling buffer C see Appendix 2J; (iii) 2\xl of bovine serum 
albumin (lOmg/ml); (iv) DNA in agarose (up to 32,5pl); (v) 5pl of
cx- [3^P]dATP (Amersham, lOpCi/p.1); (vi) 2units of Klenow enzyme 
(Boehringer Mannheim). The reaction was stopped by the addition of 
200pl STOP buffer.
2.1v. m. AutoradiographV
Filters were covered with Saran Wrap and mounted in a light
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proof cassette. A sheet of X-ray film (X-OMAT S) (Kodak) was placed 
next to the filter. Autoradiographs were stored at -70'C with
intensification screens or at room temperature.
Film was developed (Kodak DX80) for 4 minutes in a dark room, 
fixed for 4 minutes (Kodak FX40), then washed extensively under the 
tap and hung to dry.
2.iv.n. Removing probe from filters
Hybond-N filters were incubated at 45°C for 30 minutes in 0. 4M 
NaOH, then transferred to 0.IxSSC, 0.1% ("7^) SDS, 0.2M Tris-HCl, 
pH7. 5, and incubated at 45*C for a further 30 minutes to allow 
total removal of probe. Membranes were wrapped in Saran Wrap and 
exposed to X-ray film to ensure the successful removal of probe. 
Damp filters were stored, wrapped in Saran Wrap, at 4'C in the
dark.
2.iv.o. Colony hybridisation
B. pertussis and E. coli strains were grown up in microtitre 
trays and the OD^sanm of the cultures recorded in an ELISA plate 
reader. Culture samples of 75pl were filtered onto nitrocellulose 
using a 96 well mini-fold apparatus (Schleicher and Schuell). To 
lyse the cells and bind the DNA to the filter, the nitrocellulose 
was placed on Whatman No. 3 paper soaked in 0.5M NaOH, cells upward, 
for 10 minutes. Then the filter was neutralised by placing on
Whatman No. 3 soaked in IM Tris-HCl pH7.5, twice, each for 2 
minutes. The nitrocellulose was then transferred to paper soaked in 
0. 5M Tris-HCl pH7. 4, 1. 5M NaCl and left for 5 minutes. The filter
was dried at 37'C, then baked for 2 hours at 80'C in a vacuum oven.
Filters were pre-wet in 2xSSC, then prehybridised for 2-3
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hours at 37'C in 20ml prehybridisation solution (GxSSC, 0.2% (^7^) 
SDS, 5x Denhardt's solution, 50% (^7^) formamide, and lOOpg/ml
preboiled salmon sperm DNA), Half of the prehybridisation solution 
was removed from the bag and the nick-translated, boiled probe
added. The bag was resealed and hybridisation was left to occur 
overnight at 37'C.
After hybridisation the filters were washed (SxSSC, 0.1% ("7^) 
SDS) twice for 30 minutes at 65'C, then in 2xSSC at room 
temperature for 1 hour, dried at 37'C and mounted for
autoradiography.
2.iv.p. Nick translation
Probes were prepared using l-2pg plasmid DNA <pGS18, pColIb, 
pRMB2 or pRMBll). The reaction mix contained DNA, 20pl A solution
[see previously], lOpl lOx nick translation buffer [see Appendix
2], Ijil DNase I (Img/ml stock), Ipl DNA polymerase (5 units/pl),
distilled water to a final volume of lOOp.1 and 2.5pl ot-[ ®=^ P] dATP 
(Amersham, lOpCi/pl). After incubation at 15'C for 1 hour, the
reaction was stopped by the addition of 4pl 0. 5M EDTA. Orange G dye
was added to the sample, which was then loaded onto a Sephadex G-50
column and eluted with TES buffer. Radioactivity was monitored and 
the first peak containing the labelled DNA was collected. This was 
boiled for 5 minutes, cooled rapidly on ice and added to the
prehybridisation solution in a sealed plastic bag.
2.V Assays
2.V.a. Agglutination assay
Samples of overnight cultures of B. pertussis were mixed with
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dilutions of monoclonal antibodies (AG2A and AG3A - raised against
AGG2 and AGG3 respectively, provided by L.A.E. Ashworth; Pathology
Division, CAMR). Dilutions were made in phosphate-buffered saline (PBS 
- 0. 15M NaCl, 0. 066M Na^PO*, pH7.0), starting at a 1 in 4 dilution and 
doubling dilutions were made to a final 1 in 512. This assay was 
carried out in U-shaped-bottomed microtitre trays, which were covered 
and left overnight at 37'C. Agglutination was noted when the cells 
clumped, while non-agglutination lead to the formation of a button at 
the bottom of the well,
2.V.b. Haemagglutination assay
Horse red blood cells (InterMed) were washed three times in PBS. 
Concentrated cells were diluted to 2% (^7^) in PBS and lOOpl mixed
with lOOpl of bacterial cells (grown in liquid culture with 
cyclodextrin). Assays were carried out in microtitre trays with U- 
shaped-bottoms, which were covered and left overnight at room 
temperature. Haemagglutination was noted where the red blood cells 
clumped, while non-ability to haemagglutinate was shown by the 
formation of a button at the bottom of the well.
2.V.c. Qualitative adenylate cyclase assay
B. pertussis strains were grown on BG overlay plates (the top
\
layer of agar alone containing red blood cells) to show the presence 
of haemolytic activity associated with the adenylate cyclase toxin. 
Cells for use in the assay were transferred to 200pl SS(MepCD+CAA+/- 
Km) and incubated for 4 days at 37'C. E.coli G802 (indicator strain - 
see Table 3) was streaked onto NA+IPTG+X-gal. A single white colony 
was used to inoculate a 10ml overnight culture in NB.
Into the wells of a sterile microtitre tray, 50pl of reaction mix
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C60mM Tris-HCl pH8. 0, lOmM MgCl^, 5mM ATP, lOrtiM CaCl^, 500units/ml
calmodulin, in distilled water) was dispensed, followed by 8pl of 
B,pertussis test culture. The mixture was Incubated for 3 hours at 
37°C, then ISOpl of test suspension was added. The test suspension was 
composed of NB+IPTG+X-gal and a 1 in 100 dilution of a fresh culture 
of the E. cold cyaA~ indicator strain. The solutions were mixed well 
and the tray incubated overnight at 37°C. B. pertussis cultures 
producing adenylate cyclase transform ATP to cAMP which is secreted
into the culture medium. Cyclic-AMP stimulates the production of p- 
galactosidase from the lac operon in the E. coll indicator strain,
which in turn utilises the substrate X-gal to produce a dark blue
colouration. Wells containing B, pertussis strains producing no 
adenylate cyclase showed no colour formation.
2.V.d. Quantitative adenylate cyclase assay
The cyclic adenosine monophoshate (cAMP) assay kit (Amersham) was 
used as in the manufacturer's recommendations, being suitable for the 
detection of 0. 2 to 16 picomoles cAMP per incubation tube. Standards 
of 1, 2, 4, 8 and 16 pmol cAMP were used, and a blank count also
performed. Test samples of 50pl were used.
Test samples were prepared using whole cells (without calmodulin) 
and X-pressed cells (with and without calmodulin). The X-press 
(Lifesciences Laboratories) was used directly on liquid cultures as 
per manufacturer's instructions. Cell extract volumes of 40pl were 
mixed with 120pl 0. 002M ATP in 0. 02M MgCl^, 80pl 0. 18M tricine pH8. 0, 
and an optional 5pl calmodulin (250 units). Controls were also 
performed with no ATP present. After incubation for 15 minutes at 
30°C, the reaction was terminated by the addition of 0.48ml 0. 05M
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Tris, 0.0005M EDTA pH7. 5 and boiled for 5 minutes. Test samples were 
stored at "20°C.
The cAMP assay is based on competition between unlabelled cAMP 
(from the test samples) and a fixed quantity of the tritium-labelled 
compound for binding to a protein which has a high specificity and 
affinity for cAMP. Samples, of 200pl volumes, from the test mixtures 
were transferred to scintillation vials containing 5ml scintillation 
fluid, mixed thoroughly and the percentage of tritiated cAMP remaining 
in solution counted in a scintillation counter.
2. vi. Animal Studies
2.vi.a. Assay for heat-labile toxin
B. pertussis strains were grown on BG agar for 2 days at 37'C. 
Cells were removed and suspended to lOou (opacity units; WHO 5^ *^  
International Reference Preparation of Opacity; Perkins et al. , 1973)
in PBS. Three-week old male mice were injected intraperitoneally (ip) 
with 0.5ml of lOou or 2.Sou doses, in groups of five. The number of 
mice surviving after 5 days was recorded.
2.vi.b. HLT skin reactions
B. pertussis cultures were diluted 1 in 3 in sterile saline and
\
50pl injected subcutaneously into the dorsal region of 3-week old male 
mice (after ether anaesthetic). After 24 hours the mice were killed 
with COz and the skin of the back removed. The size and severity of 
the zone of haemorrhage was noted,
2.vi.c. Hlstamine-sensitisation test
B. pertussis strains were grown on BG agar for 2 days at 37'C. 
Cells were removed and suspended to lOou in PBS, then heated at 56'C
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for 30 minutes. Groups of five male mice, nine weeks old, were 
injected Ip. with 0.5ml of lOou or 2.5ou doses. After 5 days each mouse 
was challenged by ip. injection with 3mg of histamine dihydrochloride 
(Sigma) in 0.5ml PBS, pH7. 4, The number of mice surviving after 3 
hours was recorded.
2.vi.d. Virulence as determined by the mouse-weight-gain test (MWGT) 
Groups of ten CD-I strain female mice, of 3-4 weeks of age, were 
challenged in. with 045ml volumes of graded doses of test samples in 
sterile 1% CAA solution. An ether anaesthetic was used. Challenge 
dilutions were started from a lOou initial suspension of each strain. 
The first three 10-fold dilutions were used as challenges, while the 
10~® dilution was used to determine viable counts. Control mice were 
left unchallenged. Mice were weighed prior to challenge and again at 
2-3 day intervals for the next three weeks. Fatalities were recorded.
After three weeks, five mice from each challenge group were 
examined for lung weight (as a percentage of body weight) and
pathology. Slices of lungs were streaked onto BG agar to identify 
remaining infection. Spleen weight as a percentage of total body
weight was also examined, and leukocyte counts perfomed.
2.vi.e. Vaccine preparation
Vaccines were prepared from B. pertussis Wellcome 28, BP347 and
the Crb~ Tn5 mutant 51. Cells were grown with shaking in liquid
culture for 24 hours, then centrifuged at 6000g for 20 minutes and
resuspended to lOOou in PBS. Suspensions were heated at 56 *C for 
30mins, thimerosal (Sigma) added to a final concentration of 0.01% as 
a preservative and the vaccines stored at 4'C.
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2.vi.f. Mouse intranasal and intracerebral protection tests
Groups of five, 3 - 4  week old CD-I strain mice, were injected ip. 
with 0.5ml vaccine (at lOou, 2ou and 0.4ou). Two groups of mice were 
left unvaccinated as controls.
Two weeks after vaccination mice were anaesthetised and 
challenged with virulent B. pertussis. Lawn plates of the challenge 
strain, B, pertussis 18-323, were prepared. Cells were suspended in a 
CAA solution to lOou (approximately 2x10® cfu/ml) and eight serial 10- 
fold dilutions made. Highest dilution samples were used for colony 
counts. The 10~^ dilution was used for intranasal (in.) challenge, 50pl 
being passed through the nasal cavities by allowing the anaethetized 
mice to Inhale. For the intracerebral (ic) challenge, 30pl of a 10~® 
dilution was injected into the brain. One group of controls were 
challenged, the other left unchallenged.
Mice were weighed every two days and any fatalities noted for a 
period of nearly 3 weeks. For mice challenged in., lung pathology was 
recorded. Lungs were weighed, examined for pathological changes and 
slices spread over BG+Ceph+Amph overlay plates. Plates were incubated 
at 37°C and signs of bacterial colonisation noted.
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RESULTS
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3.1. Transposon Delivery Systems In B, pertussis
A series of plasmids, proposed as transposon delivery vectors for 
Tn5 mutagenesis studies, were Introduced into the pathogen B. pertussis 
by conjugation. The resultant populations of B. pertussis kanamycin- 
resistant transconjugants were screened for absence of the delivery 
vehicle in order to identify the most suitable vector for Tn5 
insertional mutagenesis in this bacterium. The transposon Tn5 was re­
evaluated as a mutagen in B. pertussis by screening those kanamycln- 
resistant transconjugants not maintaining the donor plasmid for the 
presence of Tn5 DMA (to identify spontaneously kanamycin-resistant 
isolates).
3.1.a. Viable count data for donor and recipient strains during 
filter conjugations
E, coli donor strains carrying Tn5 delivery vectors [see Table 3] 
and B. pertussis recipient strains were inoculated onto filters with 
the recipient in excess, The numbers of donor organisms placed on the 
filters varied between 8.8xl0®cfu and S.OxlO^cfu per filter, while 
numbers of recipients varied between 5.9xl0^cfu and 3.5xlO®cfu' per 
fliter.
\
After incubation for 18 hours at 37“C, viable counts were 
determined. Donor strains showed an increase in cell numbers, varying 
between 2. 6xl0^cfu and 1. OxlO’"=*cfu per filter, while recipient strains 
showed only slight fluctuations in cell numbers with respect to the 
initial counts.
Differences in growth of B. pertussis strains alone were noted on 
the control filters used to Identify spontaneous kanamycin-resistance
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frequencies. Initial viable counts of B, pertussis Wellcome 28 
inoculated onto filters varied between 7.4xl0^cfu and 4. 4xl0®cfu per 
filter, while final viable counts showed a drop in cell numbers. In a 
single experiment with B. pertussis Tohama, an increase in cell numbers 
from an initial 1.6xl0®cfu to a final 7. 2xl0^cfu per filter was noted.
3.i.b. B. pertussis kanamycin-resistant transconjugants
The frequencies of B. pertussis kanamycin-resistant trans­
conjugants obtained after filter conjugations with E. coli transposon 
donor strains are shown in Table 6. The values given are a product of 
the vector transfer frequency and the transposition frequency and have 
been calculated per recipient.
The TnS' delivery vector pSUP2021 did not transfer to B. pertussis 
at a frequency high enough to produce transconjugants and this system 
was not used further. The self-transmissible plasmids pUW964, pGS9 and 
pLG221 produced kanamycin-resistant transconjugants at frequencies 
between 1.1x10”® and 5.5x10”® per recipient, while the larger self- 
transmissible plasmid pJB4JI transferred at a lower frequency.
3. 1. c. Maintenance of 'suicide' vectors
Antibiotic resistance genes carried on the transposon delivery 
vectors were used to identify the frequency of plasmid maintenance 
within populations of B. pertussis kanamycin-resistant transconjugants. 
Results of screening transconjugants from matings where vectors pJB4JI 
(Gm*^ , Sp^), pUW964 (Sp^ , Tp^) or pGS9 (Cm^) were transferred are shbwn 
in Table 6. The TnS’ delivery vector pLG221 carries no antibiotic 
resistance genes and could not be tested. B. pertussis controls showed 
no growth on antibiotic-containing media, whereas E. coli controls 
containing the relevant plasmids grew well. All the transconjugants
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Table 6 Transfer of kanamycin-resistance to B. psrtussis 
strains from E. coll transposon donors
Transposon delivery vectors [see Table 4] were 
Introduced Into the B. pertussis recipient strains by filter 
conjugations for 18 hours at 37*C [see Section 2.ill.a]. Ten 
separate matings were performed with each vector. The 
percentage of transconjugants maintaining the respective 
plasmids were deduced by screening for antibiotic 
resistances encoded by the plasmid Csee Section 2, iii.dl, or 
by probing colony dot blots with radiolabelled plasmids 
closely related to the delivery vector [see Sections 2.iv.o, 
and 2.iv.p.3. Approximately 80 transconjugants were screened 
from each different system.
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Tn5 Recipient Percentage maintenance of Frequency of
delivery strain. delivery vector from: kanamycin-
vector. resistant
1. antibiotic 11. dot blot transconjugants
resistance hybridisation (per recipient).
data. data.
pUW964 B, pert ussis 15. 6% N/D 2.9x10-®
Wellcome 28
pUW964 B. pertussis 34. 9% N/D 5.5x10-®
Tohama
pJB4JI B. pertussis 48. 8% N/D 6.6x10-7
Wellcome 28
pGS9 B. pertussis 41. 8% 30. 1% 3.5x10-®
Wellcome 28
pSUP2021 B. pertussis N/D N/D <1.9x10-® '
Wellcome 28
pLG221 B. pertussis N/D 1.' 5% 1. 1x10-®
Wellcome 28
N/D - not determined.
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tested and the controls grew on media containing no antibiotics.
The vector pJB4JI, which contains phage Mu DMA, was shown to be 
maintained in nearly half of the kanamycin-resistant transconjugants 
produced using this system. Similarly, the transposon delivery vector 
pUW964, which was introduced into two B. pertussis strains (Tohama and 
Wellcome 28), was shown to be maintained in both strains, evident by 
the presence of plasmid-encoded antibiotic resistance markers. The 
transposon donor pGS9 was also shown to be maintained in a high
proportion of transconjugants.
A second technique for the identification of B. pertussis 
kanamycin-resistant transconjugants maintaining transposon delivery 
vectors involved filtering liquid cultures onto nitrocellulose filters 
for use in culture dot-blot hybridisation experiments. Trans­
conjugants from matings where pGS9 was transferred were probed with 
pGSlS (Figure 8), while transconjugants from matings where pLG221 was 
transferred were probed with pColIb-P9 (Figure 9). Plasmid pGS18 is 
closely related to pGS9, and pColIb-P9 is closely related to pLG221, 
but neither of the probes contain Tn5 DMA [see Table 43. Delivery 
vector maintenance frequencies, obtained by probing the kanamycin- 
resistant transconjugants with plasmids closely related to the
transposon donors, are shown in Table 6. Neither probe hybridised to
B, pertussis Wellcome 28 DMA (negative control), but both probes 
hybridised to the appropriate positive controls IE. coli WA803 (pGS9) 
and E, coli HBlOl (pGS18), for the pOS18 probe, and E. coli C600 
(pLG221) and E. coli W3110 (pColIb~P9), for the pColIb-P9 probe].
The colony dot-blot hybridisation results confirmed that the 
transposon delivery vector pGS9 was maintained in between 30-40% of
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Fig. 8 Culture dot blot hybridisation of B. pertussis
kanamycin-resistant transconjugants (from matings with 
E, coll WA803 pGS9). probed with pGS18
Seventy-nine kanamycin-resistant transconjugants of
B. pertussis Wellcome 28 were screened to identify the maintenance 
of the transposon delivery vector pGS9 by hybridisation with 
pGS18 [see Section 2.iv.ol. The probe was labelled by nick 
translation for 1 hour at 15°C [see Section 2.iv,p].
Controls
A. 5. pertussis Wellcome 28; negative control.
B. E. coli WA803 (pGS9); positive control.
C. E. coli HBlOl (pGS18); positive control.
Interpretation
Columns
3 4 5 6 7
w
8 10
/ - Blank
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Fig. 9 Culture dot blot hybridisation of B. pertussis
kanamycin-resistant transconjugants (from matings with 
E. coli C60Q pLG221). probed with pColIb-P9
Sixty-five kanamycin-resistant transconjugants of 
B. pertussis Wellcome 28 were screened to identify the percentage 
maintenance of the transposon delivery vector pLG221 by 
hybridisation with pColIb-P9 C see Section 2.Iv.o]. The probe was 
labelled by nick translation for 1 hour at 15*C [see Section
2. iV. p3,
Controls
A.
B.
C.
5. pertussis Wellcome 28; negative control. 
E. coli C600 (pLG221); positive control.
E. coli W3110 (pColIb-P9); positive control.
Interpretation
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the B. pertussis transconjugants. However, the ColIb-P9 based vector 
pLG221 was shown to be a more truly 'suicidal' transposon delivery 
vehicle for use in this bacterium, since only a single transconjugant 
from the 65 Isolates tested gave a positive hybridisation signal when 
probed with pColIb-P9 [see Fig. 9;- column 1, row 2],
3.i.d. Spontaneous kanamycin-resistance in B. pertussis
The frequency of spontaneous kanamycin-resistance in B. pertussis 
Tohama was shown to be less than 1 in 2.9xlO®cfu. However, in 
B. pertussis Wellcome 28 the frequency of spontaneous kanamycin 
resistance was shown to be less than 1 in 8xl0®cfu due to poor growth. 
Since this could be problematic in further Tn5" mutagenesis 
experiments, groups of strain Wellcome 28 kanamycin-resistant 
transconjugants were probed with Tn5 (to confirm that the antibiotic 
resistance was associated with introduction of the transposon). The 
Tn5 probe did not hybridise to B. pertussis Wellcome 28 (the negative 
contï-ol), nor to E. coli strains carrying plasmids pGSlS or pColIb-P9. 
The probe did, however, hybridise to the positive control strains 
E. coli WA803 (pGS9) and E, coli C600 CpLG221). All of the putative
transposon-insertion mutants tested (over 140 individual isolates) 
were shown to hybridise to Tn5 (not shown). This suggests that 
spontaneous resistance to kanamycin is a rare event in B. pertussis 
Wellcome 28 and unlikely to be a detrimental influence on further 
mutagenesis experiments.
3.11. Production and Screening of B. pertussis Tn5 Mutants
The first step in the targeting of specific genes by Tn5 
insertional mutagenesis is the creation of a large library of mutants.
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The library may then be either laboriously screened for loss of the 
desired characteristic, or alternatively, a selective proceedure may 
be used which eliminates the unwanted mutants, or reduces the number 
which require screening. Both possibilities were explored during this 
study.
3. ii. a. Ins’ mutagenesis of B. pertussis Wellcome 28
Tn5" insertional mutants of B, pertussis Wellcome 28 were isolated 
after 5 hour conjugations on BG agar with E, coli C600 CpLG221). Growth 
to single colonies on SSA(MepCD+Km+Ceph+CR) allowed the classification 
of mutants into two groups; i. those able to bind Congo red (Crb+), 
and ii. those unable to bind Congo red (Crb“). A total of 280 mutants, 
from 31 separate matings, were colony-purified and stored. Mutants 1 - 
99 were picked from selective plates prepared with a batch of Difco 
Bacto agar previously shown to select against phase I organisms [C.J. 
Duggleby, personal communication; see Section 2,ii.a.]. Mutants 100 - 
280 were obtained without this selective pressure.
3.11.b. Spontaneous mutants unable to bind Congo red
No spontaneous Crb“ mutants were identified from colonies grown 
on CSM+CR plates, giving a spontaneous frequency of mutation from'the 
Crb^ phenotype to the Crb“ phenotype of less than 1 in 3xl0-*cfu. 
However, colony counts on CSM+CR prepared with the batch of agar 
previously shown to be inhibitory to growth of phase I organisms, were 
reduced approximately 1000-fold and Crb~ mutants were shown to 
comprise up to 30% of the residual colonies.
3.11.c. Transposon mutants unable to bind Congo red
The following identification numbers were given to twelve Crb~ 
transposon mutants identified during this study:- 15, 51, 73, 97, 98,
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99, 100, 101, 104, 113, 115 and 268. Mutants 51 and 73 were obtained
from the same filter mating, as were the following pairs, i. 98 and
99, ii. 100 and 101, and lii. 113 and 115. A single mutant (numbered 
102) with reduced ability to bind Congo red (Crb*^-) was also 
identif ied.
3. ii. d. Antigenic modulation in Crb~*~ mutants
Mutants 1 - 120 (excluding Crb“ mutants) were grown at 25°C on 
CSM+CR to show alteration of the Congo red-binding phenotype during 
antigenic modulation, or, alternatively, to identify mutants unable to 
modulate. However, all of the Crb+ (red) colonies tested showed the 
ability to modulate, growing as Crb" (pale) colonies under this C-mode 
growth condition.
3.11.e. Expression of heat-labile toxin in transposon mutants
The expression of heat-labile toxin (HLT) in over two hundred 
Crb+ mutants was tested. Mice were injected intradermally with live 
bacterial suspensions and examined for skin reactions after 24 hours. 
In the majority of cases, the size and severity of the zone of 
haemorrhage was large, similar to that found with the positive control 
strain B. pertussis Wellcome 28. Injection with the negative control,
BP347, caused only very slight haemorrhage. Mutants which caused low
levels of skin reactions were retested in the lethal mouse model, in 
which cell suspensions were injected into infant mice and the number 
of fatalities after 5 days noted. No Crb* mutants were identified" as 
being unable to express HLT.
3.11. f. Screening Crb~ (and Crb*^-) mutants for loss of other
virulence-related character1st les
The Crb~ mutants, and the Crb*/- mutant 102, were screened for
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alterations in other properties related to virulence, including growth 
on nutrient agar (a characteristic associated with the fully avirulent 
phase IV strains). None of the mutants grew on nutrient agar. The 
results of screening for other virulence-associated properties are 
shown in Table 7.
The wild-type control strain B, pertussis Wellcome 28 was positive 
for all the virulence-associated properties tested, while the negative 
control strain, BP347, expressed none of these factors. Other strains, 
used in agglutination assays, expressed only the agglutinogens shown 
to be present by previous serotyping of the wild-type Csee Table 73.
Mutants 15, 97, 98, 99, 100 and 101 were shown to be non-
haemolytic and non-haemagglutinating, and did not express adenylate 
cyclase, heat-labile toxin, nor agglutinogens 2 and 3. Mutants 104, 
113, 115 and 268 were shown to be phenotypically equivalent to this
previous group of mutants, but were not tested for expression of heat- 
labile toxin. Both groups were considered to be equivalent to 
previously classified Vii—  strains. Mutants 51 and 73 were shown to be 
haemolytic and gave positive results in the qualitative adenylate 
cyclase assay, but were also non-haemagglutinating and produced 
neither heat-labile toxin nor agglutinogens 2 and 3. The‘Crb*/~ mutant 
(102) appeared to produce reduced levels of agglutinogen 3 and showed 
little haemagglutinating activity, while expressing apparently normal 
levels of other virulence factors.
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Table 7 Virulence-associated properties of a virulent 
strain, an avirulent strain and the Crb~ Tn5 
mut ant s
Transposon mutants altered in the Congo red-binding 
phenotype, along with appropriate controls, were screened 
for virulence-associated properties. B. pertussis Tohama 
(1,2) and B. pertussis 134 (1,3) were used as controls in
agglutination assays only. Production of haemolysin (HLY) 
was assayed for by growth on BG overlay plates, while 
adenylate cyclase (AC) was screened using the qualitative AC 
assay [see Section 2.v.cl. Agglutination assays (known 
serotypes are given in brackets) and haemagglutination (HA) 
assays were performed in microtitre trays as described in 
Sections 2.v.a. and 2.v.b. respectively. The assay for heat- 
labile toxin (HLT) was performed in infant mice, screening 
for survivors 5 days after Injection [see Section 2. vi.b].
— 89
strain
(serotype)
Virulence-associated properties:
HLY AC HA HLT AGG2 AGG3
Controls 
B. pertussis 
Wellcome 28 
(1, 2, 3)
B. pertussis 
347 (-)
B. pertussls 
Tohama (1,2) 
B,periussls 
134 phase I 
(1, 3)
N/D N/D N/D N/D +
N/D N/D N/D N/D
Crb" mutants 
15 
51 
73
97
98
99 
100 
101 
104 
113 
115 
268
+ +
+ +
N/D
N/D
N/D
N/D
Crb*/" mutant 
102 + / - +/-
N/D not determined.
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3, ill. Identification of Tn5 Insertion Sites In Mutants Altered 
in the Congo Red-Binding Phenotype 
Tn5 insertion sites, in mutants displaying either complete or 
partial loss of ability to bind Congo red dye, were identified using 
Southern blots prepared with three different restriction enzyme 
digests. The blots were probed with ®^P-radiolabelled restriction 
fragments of Tn5. Radiolabelled X-Hindlll markers were used, as a 
reference, to identify the sizes of the restriction fragments which 
hybridised to the probe Csee Section 2.iv.g].
3. Hi. a. Tn5~ insertion sites in BamHI restriction fragments
BamHI digests of chromosomal DNA from the Crb" mutants and the 
Crb*/" mutant were probed with the internal Hindlll fragment of Tn5 
(Figure 10), The probe (which does not cover the major parts of the IS
elements of this composite transposon) was shown to hybridise to two
distinct bands in each digest, since BamHI cleaves Tn5" into two 
slightly asymmetrical fragments Csee Fig. 61. No hybridisation to the 
DNA of the parent strain B. pertussis Wellcome 28 was observed.
The sizes of the transposon-interrupted BamHI fragments in the
Crb" and Crb*/" mutants (shown in Table 8) were calculated after first 
identifying the sizes of individual bands hybridising to the probe 
[see Section 2.iv.h.]. To take account of the 5.8kb Insertion of Tn5, 
this value was subtracted from the summated values of those bands 
hybridising to the probe in each mutant. The interrupted BamHI 
fragment in BP347 was shown to be 15.Okb C(9.4kb + 11.4kb) - 5.8kb = 
15.Okb], in agreement with previous studies (Stibitz et al., 1988).
Similarly sized fragments were identified in mutants 100 and 101, but
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Fig. 10 Tn5-hybridisatlon to Southern blots of BamHl-digested 
chromosomal DNA from B. pertussis Crb" and Crb*/" 
mut ant s
BamHI-digested DNA fragments from B. pertussis Crb" and 
Crb*/" transposon mutants and radiolabelled X-Hindlll markers 
[see Section 2.iv.g.] were separated by electrophoresis on a 
0.6% agarose gel in 0.5xTBE, at 30mA, for 20 hours. DNA was then 
transferred by suction to a nylon membrane and probed with the 
internal Hindlll fragment of Tn5. X-ray film was exposed to the 
washed filter for 2 days, at -70“C, then developed.
Controls
A. B. pertussis Wellcome 28; negative control.
B. BP347; positive control.
Transposon mutants (this study)
c. 15. J. 101.
D. 51. K. 104.
E. 73. L. 113,
F. 97. M. 115.
G. 98. N. 268.
H. 99. 0. 102.
I. 100.
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Table 8 Size analysis of restriction fragments, from Crb" 
and Crb*/" mutants, interrupted by TnB or 1S50 
insertions
Chromosomal DNA preparations from Wellcome 28, BP347
and transposon mutants altered in the Congo red-binding 
phenotype, were digested with restriction enzymes BamHI. 
Sail. or EcoRI. DNA fragments were separated on agarose gels 
along with radiolabelled X-Hindlll size markers [see 
Sections 2.iv.f. - 2. iv.h.3. DNA fragments stained with
ethidium bromide were examined under uv light, photographed 
and transferred onto H y b o n d - N ^ "  membrane [see Section 
2.iv.i]. Hybridisation conditions were as in Section 2.iv.j. 
and Appendix 2.
Restriction length fragment probes of Tn5 were prepared 
[see Section 2. iv.k.] and labelled using the random hexa- 
nucleotide technique of Felnberg and Vogelstein (1983). 
Hybridisation with the Hindlll fragment of Tn5 Identified 
Tn 5" insertions in BamHI. Sail and EcoRI restriction 
fragments, while the larger Hpal fragment of Tn;5 was used to 
identify sizes of restriction fragments interrupted by 
either Tn5 or IS50 in the EcoRI digests alone.
The sizes of restriction fragments Interrupted by Tn5 
or ISBO were deduced from Figures 10, 11 and 12, and are
shown after the sizes of the transposable genetic elements 
(5.8kb and 1.5kb respectively) have been subtracted.
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Restriction enzyme digests (inserted transposable 
genetic element);
Strains BamHI
(Tn5)
Sail
(Tn5)
EcoRI
<Tn5)
EcoRI 
(IS BO)
Controls 
B, pertussis
Wellcome 28 - - - -
B. pertussis
347 15.Okb 
Transposon mutants (this
1. Okb
study)
2. 7kb
15 40.Okb 7. Okb 5, 7kb 1. 2kb
51 30. Okb 13.Okb 2. Ikb 13. Okb
73 30.Okb 13.Okb 2. Ikb 13, Okb
97 30. Okb 11. Okb 10.8kb 2. 7kb
98 28. Okb 9. 5kb 3. 5kb 15.9kb
99 28.Okb 9. 5kb 3. 5kb 15. 9kb
100 15.Okb 0. 6kb 2. 5kb -
101 15. Okb 0. 3k b 2. 5kb -
104 40. Okb 25.Okb 5. 2kb Multiple
113 14. Okb 4. ikb 9. 3kb -
115 18.Okb 3. 8kb 15.Ikb -
268 40.Okb 7. Okb 2. 3kb 2. 9kb
102 9. Okb 2. 8kb 3. 5kb
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with the transposon positioned less symmetrically than in BP347, The 
sizes of the interrupted fragments in the other TnB mutants were shown 
to vary from 9. Okb in the Crb*/" mutant 102, to approximately 40kb in 
mutants 15, 104 and 268. Mutants 51 and 73 appeared to have identical
TnB insertion sites, as did mutants 98 and 99.
3.111. b, TnB insertion sites in Sail restriction fragments
Sail digests of chromosomal DNA from the Crb" mutants and the 
Crb*/" mutant were probed with the internal Hindlll fragment of TnB 
(Figure 11). The TnB probe was shown to hybridise to two distinct 
bands in each mutant chromosomal DNA digest, since TnB has a central 
Sail cleavage site 1 see Fig, 61. No hybridisation occured with 
B, pertussis Wellcome 28 DNA.
The sizes of the interrupted Sail restriction fragments 
(calculated as above) were shown to vary from 0.3kb in mutant 101, to 
approximately 25kb in mutant 104 (Table 8). Mutants 51 and 73 were 
confirmed to have identical transposon insertions, as were mutants 98 
and 99. The presence of faint bands in addition to the expected 
doublets were noted in some digests of the mutated DNA. These bands 
may have been caused by incomplete digestion or, alternatively, by
separate 1S50 transposition events (visible since a very small portion
\
of the IS elements were included in the probe).
3.111. c. TnB Insertions in EcoRI restriction fragments
EcoRI digests of chromosomal DNA from the Crb" mutants and the 
Crb*/" mutant were probed with the internal Hindlll fragment of TnB 
and the internal Hpal fragment of TnB (Figure 12). While the smaller 
Hindlll fragment encompasses only the central antibiotic containing 
region of the transposon, the larger fragment includes most of the two
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Fig. 11 Southern blot of Sall-digested chromosomal DNA from
B. pertussis Crb~ and Crb*/" mutants, hybridised with
TnB
Sall-digested DNA fragments of B. pertussis Crb" and Crb*/" 
transposon mutants were separated by electrophoresis overnight, 
at 20mA, on a 0.8% agarose gel, in 0.5xTBE, with radiolabelled X- 
Hlndlll size markers C see Section 2. iv.g]. The DNA pattern was 
transferred to a nylon membrane and probed with the internal 
Hindlll fragment of TnB [see Sections 2.iv. i - 2.iv.13. The
filter was washed and subjected to autoradiography for 2 days at 
-70'C.
Controls
A. B. pertussis Wellcome 28; negative control.
B, BP347; positive control.
Transposon mutants (this study)
c. 15. J. 101,
D. 51. K. 104.
E. 73. L. 113.
F. 97. M. 115.
G. 98. N. 268.
H. 99. 0. 102.
I. 100.
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Fig.12 Hybridisation of a Southern blot of EcoRI-digested 
chromosomal DNA from B. pertussis Crb" and Crb*/" 
mutants, with Tnff
EcoRI-digested chromosomal DNA fragments of B. pertussis Crb" 
and Crb*/" transposon mutants were separated by electrophoresis 
overnight, at 30mA, on a 0. 7% agarose gel, in IxTBE, with 
radiolabelled X-Hindlll size markers [see Section 2.iv. g]. DNA 
was transferred to a nylon membrane and probed with the internal 
Hpal restriction fragment of Tn5 [see Sections 2.iv.i - 2.iv.13. 
TnB insertions were identified by comparison with a TnB Hindlll 
probed blot, while additional bands were proposed to have arisen 
from ISBO transposition events.
Controls
A. B. pertussis Wellcome 28; negative control.
B. BP347; positive control.
Transposon mutants (this study)
c. 15. J. 101.
D. 51. K. 104.
E. 73. L. 113.
F. 97. H. 115.
G. 98. N. 268.
H. 99. 0. 102.
I. 100.
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terminal, independently mobile, IS50 elements which flank the central 
area [see Fig. 63. Tn5 contains no internal EcoRI restriction sites, 
so a single restriction fragment was expected to hybridise to the 
probe when only a single Tn5" transposition event had occured. Such 
expected results were obtained using the Tn5 Hindlll probe and were 
used to calculate the sizes of the Tn5-interrupted EcoRI fragments, 
which, after subtraction of the 5.8kb transposon DMA, are shown in 
Table 8. Single Tn5 insertions were noted in each mutant, while the
probe showed no hybridisation to the parent strain.
Faint hybridisation signals, in addition to the single expected 
bands, were noted in some digests after probing with the Hindlll 
fragment of Tn5. These bands gained in strength when the alternative 
Hpal digested probe, which encompasses almost the entire transposon, 
was used. The presence of additional bands were presumed to be due to 
separate IS50 transposition events. The size of the IS50-interrupted 
EcoRI fragments are shown in Table 8 and have been calculated by 
subtracting the size of a single IS5# element <1. 5kb) from the size of 
hybridising bands not previously ascribed to TnS" insertions. A single 
mutant, 104 <K), appeared to have multiple IS50 insertion dites. 
Mutants 51 and 73 were shown to have identical Tn5 and 1S50 insertion
sites, as were mutants 98 and 99. BP347 and mutants 100, 101, 113, 115
and 102 showed no independent IS element transposition events.
3. Iv. Complementation of the Crb~ Transposon Mutants with the
Cloned bvg Locus
The cloned bvg locus, present on pRMB2 and on the pRMB2 deletion 
derivative pDMl Csee Fig. 73, was introduced into the B, pertussis Crb~
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transposon mutants. Complementation in trans of mutations in the bvg 
locus were screened for by regained expression of certain virulence- 
associated properties.
3.iv.a. Complementation studies with pRMB2
The cosmid pRMB2 was Introduced into B.pertussis Wellcome 28 Crb~ 
Tn5 mutants by 5 hour tripartite conjugation on BG agar with the 
E, coll donor strain DHl (pRMB2> and E. coll HBlOl containing the 
mobilising plasmid pRK2013 C see Table 43. Transfer of the cosmid was 
monitored by the acquisition of tetracycline resistance in the 
B, pertussis recipients.
The kanamycin/tetracycline resistant transconjugants were colony 
purified, then streaked onto BG overlay plates (containing the 
appropriate antibiotics) to determine if haemolytic activity had been 
reacquired. Additionally, transconjugants were grown to single 
colonies on CSM+Km+Ceph+Tc+CR to screen for Congo red uptake.
Table 9 shows the expression of certain virulence-associated 
properties by Crb" transposon mutants after complementation in trans 
with the bvg locus on pRMB2. All the mutants regained the ability to 
take up Congo red dye. Additionally, all the non-haemolytlc mutants
regained the ability to lyse horse red blood cells.
\
3.iv.b. Complementation studies with pDMl
The pRMB2 deletion derivative pDMl was introduced into the 
B.pertussis Crb~ transposon mutants by conjugation with E. coll JM83 
(pDMl), using the helper plasmid pRK2013. A comparison of the effects 
of complementation in trans with pDMl, against those of pRMB2, could 
provide Information on the role of the 12kb deleted region of pDMl 
[see Figure 73 in virulence regulation.
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Table 9 Complementation of Crb~ transposon mutants with 
the cloned bvg locus on pRMB2 or pDMl 
The cloned bvg locus was introduced into the 
B. pertussis Crb~ transposon mutants, on either pRMB2 or its 
deletion derivative pDMl, during 5 hour plate conjugations 
utilising the helper plasmid pRK2013 Csee Section 2. iii.b. ]. 
Transconjugants containing the bvg locus were screened for 
the regain of Congo red-binding ability and haemolysis 
CHLY).
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Expression of virulence-associated properties 
by Crb“ mutants containing the hvg locus on 
pRMB2 or pDMi:
Strains CR-blnding 
pRMB2 pDMl
HLY
pRMB2 pDMl
Control
BP347 + + + +
Transposon mutants (this study)
15 + + + +
51/73 + + N/D N/D
97 + + + +
98/99 + + + +
100 + + + +
101 + + + +
104 + + +
113 + + +
115 + + +
268 + + +
N/D - not determined.
— 104—
Alterations in the Congo red-binding phenotype and in the 
haemolytic nature of the transconjugants were noted after 
complementation in trans with pDMl and are shown in Table 9. All of 
the previously Crb~ mutants, including BP347, showed regained ability 
to take up Congo red dye, while those mutants originally non- 
haemolytic all regained the ability to lyse horse red blood cells.
3.iv.c Instability of bvg clones
During complementation studies involving either pRMB2 or pDMl it 
was noted that the cloned bvg locus on these plasmids appeared to be 
unstable. Although tetracycline resistant transconjugants of all the 
Crb~ mutants were obtained which showed regained expression of 
virulence-associated properties, some transconjugants showed no return 
to virulent characteristics. The presence of plasmid DNA in these 
tetracycline-resistant recipients was not screened for, nor was the 
intrinsic tetracycline-resistance level of B. pertussis ascertained.
3. V. Hybridisation of the Crb^ and Crb^-^~ Transposon Mutants with
the bvg Locus on pRMB2
The regained expression of virulence-associated factors, in- the 
Crb~ mutants isolated during this study, after complementation in 
trans with the bvg locus, indicates that the mutations causing the 
Crb“ phenotype could all have been within this locus. Previous 
results, however, have suggested the mutations (if in the bvg region) 
were not all caused by transposon Insertions. The Southern blots used 
to identify Tn5 insertion sites in the Crb“ mutants were washed to 
remove the unwanted probe, then reused to identify transposon 
insertions, or alternative genetic rearrangements, in the hvg locus by
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probing with labelled pRMB2 DNA.
3.V,a. EcoRI-digested chromosomal DNA blots probed with pRMB2
A Southern blot of EcoRI-digested chromosomal DNA from the 
transposon mutants was probed with ^^P-radiolabelled pRMB2 DNA (Figure 
13). Hybridisation patterns from the mutant genomes were compared with 
the wild-type pattern, to identify the sites of Tn5 insertion or 
alternative genetic rearrangements which could have affected 
expression of those virulence factors under bvg control.
Figure 13 shows the labelled pRMB2 DNA to have hybridised to five 
bands of the following sizes on a Southern blot of B, pertussis 
Wellcome 28 EcoRI digested DNA (A): 2. 5kb, 2.7kb, 4.7kb, 5. Ikb and
approximately lOkb. A further band of l.bkb was seen only faintly and 
is not shown on Fig. 13. The hybridising bands define the bvg locus 
(2, 5kb and 2. 7kb bands), the fbaB gene (lOkb band) and a non­
contiguous fragment (4, 7kb, 5. Ikb and the 1. 5kb band not shown) 
present on pRMB2 [see Fig. 73.
When probed with pRMB2, the 2.7kb EcoRI band, shown in the wild- 
type strain, was not present in the transposon mutant BP347 (B), which 
was originally used to define the vir ibvg') locus. However, this
mutant showed hybridisation to an additional band of 8.5kb, which
\
corresponds to an insertion of the 5.8kb transposable genetic element 
Tni) in the 2.7kb EcoRI fragment. Similar transposon insertions in the
2. 5kb EcoRI fragment of the bvg locus are visible in mutants 100 '(I) 
and 101 (J), where the smaller band is replaced by a signal at
approximately 8.3kb. Deletions of genetic material were identified in 
mutants 97 (F) and 104 (K), In mutant 97 the deletion was shown to 
consist of approximately lOObp from the 2.7kb EcoRI fragment. A larger
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Fig. 13 Autoradiograph of EcoRI-digested chromosomal DNA from 
transposon mutants probed with the bvg locus on pRMB2
A Southern blot of EcoRI-digested chromosomal DMAs from the 
transposon mutants altered in the Congo red-binding phenotype and 
B. pertussis Wellcome 28 was probed with radiolabelled pRMB2 DNA 
(plasmid was supplied by D, MacGregor and labelled by nick 
translation; see Section 2.iv.p). After autoradiography for 2 
days at -70“G, with intensification screens, the film was 
developed.
Controls
A. jR. peritissis Wellcome 28; wild-type.
B. BP347; Tn5 insertion in bvgC.
Transposon mutants (this study)
c. 15, J. 101.
D. 51. K. 104.
E. 73. L. 113.
F. 97. R 115.
G. 98. N. 268.
H. 99. 0. 102
I. 100.
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region was missing in mutant 104, the deletion apparently covering the 
entire hvg locus and the fhaB gene [see Fig. 71. However, the probe 
hybridised to two small, additional, fragments (2. 3kb and 2. 9kb) in 
the EcoRI digest of mutant 104 DNA, suggesting the ends of the 
deletion were within the area covered by the probe. The remaining Crb" 
mutants showed no transposon insertions or genetic rearrangements, 
having hybridisation patterns in common with the wild-type strain.
3.V.b. BamHI-digested chromosomal DNA blots probed with pRMB2
Radiolabelled pRMB2 was used to probe a Southern blot of BamHI- 
digested chromosomal DNA from the Crb~ and Crb+/- transposon mutants 
and controls (.B. pertussis Wellcome 28 and BP347). The resultant 
hybridisation patterns were examined as previously.
When probed with pRMB2, B. pertussis Wellcome 28 BamHI-digested 
DNA showed hybridisation to seven bands of the following sizes: 1.5kb,
2. 4kb, 2. 8kb, 3. Okb, 5. Okb, ll.Bkb, and 15. Okb. A faint additional 
band, of approximately 4.5kb, was also noted and may have been caused 
by incomplete digestion at the BamHI site between the 1.5kb and 3.Okb 
restriction fragments. In the transposon mutant BP347 the probe showed 
no hybridisation to the 15.Okb BamHI fragment, but alternatively
hybridised to two smaller bands of approximately 9. 4kb and 11.4kb
\
(identifying and positioning the Tn5 insertion site within the 15.Okb 
BamHI restriction fragment, since Tn5 has an internal BamHI site). 
Transposon insertions were similarly identified in mutants 100 (I) and 
101 (J), both within the 15. Okb BamHI fragment and positioned close to 
the insertion in BP347. A large deletion was evident in mutant 104 
(K), covering both the bvg locus and the fbaB gene [see Fig. 7J, 
whilst the small lOObp deletion, previously noted in mutant 97, was
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not apparent in the large 15kb fragment. The remaining mutants 
displayed hybridisation patterns similar to the wild-type, 
unmutagenised strain.
3. vl. Frameshlft Mutagenesis and the Identification of Spontaneous
Crb~ Mutants
The insertion of a single nucleotide base at a specific site 
within the bvg locus has been proposed as one mechanism for phase 
variation in B,pertussis (Stibitz et al., 1989). Growth of B. pertussis 
strains in the presence of a frameshift mutagen could, therefore, be 
expected to cause phase variation (from Vir^ 4 Vir~ and from Vii—  4 
Vir* forms) at frequencies considerably higher than the spontaneous 
event. The Crb~ mutants created in this study, which had hitherto 
unidentified mechanisms causing loss of virulence-associated 
characteristics, could be identified as frameshift mutants if a high 
frequency of revertants could be induced using the mutagen ICR 191 
(since ICR 191 can cause the insertion or deletion of single or 
multiple bases).
3.vi.a. Spontaneous phase variation in B. pertussis
Liquid cultures of B. pertussis Wellcome 28 (Crb^G and B. pertussis 
L84 phase I Crb“ (a spontaneous Crb~ mutant [see Section 2.1.3) were 
incubated at 37°C with shaking for 48 hours, diluted in PBS and plated 
onto agar containing Congo red. No phase variants were identified for 
either strain, although over 5000 colonies were screened.
3.vi.b. Resistance of B, pertussis to ICR 191 in liquid culture
The resistance of B. pertussis Wellcome 28 to ICR 191 was 
identified by innoculating liquid cultures with different
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concentrations of mutagen and incubating, with shaking, in the dark 
for 24 hours (ICR 191 can induce deletion mutations or alternative 
genetic rearrangements in bacterial genomes in the presence of light). 
Flasks containing no mutagen showed good growth, whilst those with an 
ICR 191 concentration of less than 2. Opg/ml showed some growth. 
Concentrations of mutagen over 4. Ojjig/ml totally inhibited growth.
These experiments were repeated using a longer incubation period, 
of 48 hours, and with only low levels of mutagen, to identify the 
range of concentrations of ICR 191 which were not so inhibitory as to 
cause total cell death, but where mutation in the cell was high. 
Figure 14 shows the effect of increasing ICR 191 concentration on cell 
numbers. An appropriate range of mutagen concentration for frameshift 
mutagenesis in B.pertussis was identified as being between 0.7pg/ml 
and i.Opg/ml, since at these concentrations cell numbers were reduced 
between 100- and 1000-fold.
3.vl.c. Phase variation in B. pertussis by frameshift mutagenesis 
on agar plates
Liquid cultures of B. pertussis Wellcome 28 and B, pertussis L84 
phase I Crb“ were grown up for 24 hours, diluted in PBS and plated
onto CSM+CR, with the following additions to a central well, i. no
\
mutagen, ii. 50pl stock solution ICR 191 (Img/ml), and iii. lOOpl 
stock solution ICR 191. After incubation for 5-6 days at 37°C the 
plates were examined. Approximately 2000 colonies grew on each plate, 
but zones of inhibition in plates containing mutagen were noted around 
the central well where the mutagen was added (and hence at the highest 
concentration). However, no phase variants were identified by a change 
in ability to bind Congo red. The presence of high concentrations of
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Fig. 14 The effect of ICR 191 concentration on B. pertussis
growth
B. pertussis Wellcome 28 was grown with shaking in 
liquid cultures for 48 hours at 37°C, in the dark, with 
various concentrations of ICR 191- Cultures were diluted in 
PBS and used to inoculate BG plates. After incubation at 
37“C for 5 days, colony counts were made and the results 
plotted on the graph.
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mutagen appeared to affect the CR dye (causing a slight colour change 
and potentially affecting uptake), so colonies were replica plated 
onto CSM+CR containing no mutagen. Good growth, in the same patterns 
as on the original plates was observed, but no phase variants were 
identlfled.
3.vi. d. Induced phase variation in B, pertussis by frameshift 
mutagenesis in liquid culture 
Liquid cultures of B. pertussis Wellcome 28 and B. pertussis L84 
phase I Crb~ were Incubated at 37“C, with shaking, in flasks 
containing either no mutagen, or 0.7pg/ml ICR 191. After Incubation 
for 22 hours, 28 hours, 45 hours, 52 hours and 70 hours, samples of 
the cultures were diluted In PBS and plated onto CSM+CR.
In the absence of mutagen no phase variants were identified from 
B.pertussis Wellcome 28 cultures at any of the sampling times. When 
mutagen was present no phase variants were noted from samples taken at 
22 and 28 hours from the B, pertussis Wellcome 28 culture. However, at 
sampling times of 45 hours and 52 hours the same cultures showed a 
ratio of 1 Crb~ (pale) mutant to every 3000 Crb+ (red) mutants.
In B. pertussis L84 phase I Crb~ no phase variants were Identified
after Incubation In the presence, or in the absence, of mutagen.
\
3.vi.e. Induced phase variation in B, pertussis Crb~ transposon 
mutants by frameshift mutagenesis in liquid culture 
Those mutants which might have gained the Crb" phenotype by 
spontaneous point mutations within the bvg locus were studied under 
conditions used to Induce frameshift mutations in B, pertussis Wellcome 
28 [see Section 3.vl.d.]. The Crb~ Tn5 mutants (test Isolates and 
negative controls) and B. pertussis Wellcome 28 (positive control) were
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grown In liquid culture for 48 hours in the presence 0. 7pg/ml ICR 191. 
B.pertussis Wellcome 28 and mutants 51 and 113 were also grown in the 
absence of mutagen to act as controls to determine the spontaneous 
mutation rate. Cultures were incubated with shaking in the dark for 48 
hours, prior to dilution and plating onto CSM+CR. After 5 days at 37°C 
colony counts were made to assess the number of red and pink colonies 
present In each culture.
B. pertussis Wellcome 28 showed the same spontaneous and Induced 
phase variation frequencies as previously [see Sections 3,vl.a. and 
3.vi.d.1. Additionally, no spontaneous phase variants were Identified 
on plates of mutants 51 and 113. Mutants 51, 98, 113 and the negative
control 104 (a deletion mutant) also showed no Induced phase variants. 
However, mutant 15 showed good growth <4xlO®cfu/ml) and an Induced 
phase reversion frequency of 1 in 4000cfu. Induced phase variation, 
due to frameshift mutagenesis, was not studied in mutants 115 and 268.
3.vll. Studies on Crb~ Mutant 51
Mutant 51 was identified as a Crb~ Isolate after transposon 
mutagenesis experiments. During screening for virulence factors, 'this 
mutant (and the identical isolate 73) was shown to be haemolytic and 
express adenylate cyclase (in a qualitative assay) in the absence of 
other virulence factors.
3.vll, a. Virulence-associated characteristics
Mutant 51 was previously shown not to express heat-labile toxin, 
nor agglutinogens ■ 2 and 3, and to be unable to haemagglutlnate red 
blood cells [see Table 7J. Further studies were performed to provide a 
more complete picture of the virulence-associated characteristics of
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this mutant. The results of these studies (Table 10) showed the mutant 
with all the characteristics of a Vir“ strain, but for the expression 
of the cyah gene.
The haemolytic activity of mutant 51 and the^cyclase production 
suggested this mutant to be of potential Interest for protection 
studies in animals. The level of adenylate cyclase activity was 
therefore determined in the quantitative cAMP assay (Amershara), using
B. pertussis Wellcome 28 and mutant 102 as positive controls, and BP347 
(Vlr“) and BP348 (Adc") as negative controls. The assay was performed 
on X-pressed cell extracts (prepared as previously), with and without 
ATP, in the presence of calmodulin. Results are shown in Table 11. The 
control strains tested in this assay showed the expected cAMP levels 
(high in Wellcome 28 and mutant 102, and low in mutants BP347 and 
BP348) and little cAMP production when the substrate ATP was absent. 
However, mutant 51 showed no production of cAMP, either in the 
presence or absence of ATP. This result suggests that the qualitative 
adenylate cyclase assay may not be reliable.
3. vll. b. Virulence studies In Infant mice
The virulence of mutant 51 was studied In Infant mice, using two
positive controls (18-323 and Wellcome 28) and BP348 (Adc~). Groups of
\
10 mice were challenged with 10“'', 10“^ and 10“® dilutions of a lOou
(approximately lo'cfu/ml) suspension of each strain. A 10“® dilution 
of the challenge was used for colony counts. Control mice were left 
unchallenged. The weights of the groups of challenged and unchallenged 
mice, over a three week period, are shown In Figures 15 and 16.
After three weeks, groups of five mice previously challenged with 
the different strains, were examined for signs of infection. Leukocyte
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Table 10 Virulence-related characteristics of mutant 51
Transposon mutant 51 was identified as a Crb~ mutant 
after growth on CSM+CR. However, during growth on BG agar 
the mutant showed haemolytic activity. Adenylate cyclase was 
assayed for by a qualitative proceedure C*Dr. C.J. Duggleby, 
personal communication; see Section 2.v.c). Heat-labile 
toxin was tested for in infant mice, using both a lethal 
test [see Section 2. vl. a] and a skin reaction assay [see 
Section 2.vi.bl. The mutant was shown to produce neither 
agglutinogen 2 or 3 using monoclonal antibodies in a 
microtitre tray agglutination assay [see Section 2,v.a]. 
Pertussis toxin and filamentous haeraagglutinin were assayed 
by ELISA courtesy of Dr. A. Gorringe*’. The mutant was 
additionally shown to be unable to haemagglutlnate red-blood 
cells [see Section 2. v.b]. The lack of X-mode specific 
polypeptides in mutant 51 was identified by Dr. A. Robinson 
after SDS polyacrylamide gel electrophoresis*^.
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Virulence factors Expression
Haemolysin +
Adenylate cyclase* +
Heat-labile toxin
Agglutinogen 2
Agglutinogen 3
Pertussis toxin*’
Filamentous haeraagglutinin*’
Virulence characteristics Possession of characteristic
Congo red-binding 
Haemagglut ination 
X-mode specific polypeptides 
Growth on nutrient agar
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Table 11 Cyclic-AMP production by mutant 51
The production of cAMP by the transposon mutant 51 was 
tested using the Amersham cAMP detection kit. X-pressed cell 
extracts were incubated for 15 minutes, at 30°C, in the 
presence of calmodulin, both with and without the substrate 
ATP. The kit was then used as per the manufacturer's 
recommendations. Positive controls B. pertussis Wellcome 28 
and the Crb^/“ mutant 102, and negative controls BP347 and 
BP348, were used to confirm the accuracy of the assay.
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Test sample cAMP levels (pmol cAMP/mg protein) 
+ATP -ATP
Positive controls
B. pertussis 
Wellcome 28 
Mutant 102 
Negative controls 
BP347 
BP348
Test isolate 
Mutant 51
3200
2200
167
159
300
23
145
N/D
N/D - not determined.
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Fig. 15 Virulence studies on B. pertussis strains 18-323.
Wellcome 28 and BP346. by the mouse-welght-gain 
test
The average weights of groups of ten mice, after
challenge with B. pertussis strains, are shown for a period
of 20 days.
Challenge strains
A. B. pertussis 18-323 (virulent strain).
B. P.pertussis Wellcome 28 (vaccine strain).
C. B. pertussis TnP mutant 348 (Adc~).
Challenge dilutions
♦ 10“’ dilution of a lOou suspension.
A 10“= dilution of a lOou suspension.
X 10“® dilution of a lOou suspension.
The challenge was introduced to the mice intranasally, 
whilst under ether anaesthetic. A single mouse challenged 
with the 10“’ dilution of B. pertussis 18-323 died due to the 
anaesthetic. The numbers of mice remaining alive at the end 
of the experiment are shown in brackets at the ends of the 
growth curves. [See Section 2.vi.d. 1.
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Fig. 16 Virulence studies on g. pertussig mutant 51. 
by the mouse-welght-gain test
The average weights of groups of ten mice, after
challenge with B, pertussis mutant 51, are shown for a period
of 20 days. The average weight gains of a group of 
unchallenged mice are also shown.
Challenge strains
A. B. pertussis 51 (test strain).
B. Unchallenged mice.
Challenge dilutions
♦ 10“  ^ dilution of a lOou suspension.
A 10“^ dilution of a lOou suspension.
X dilution of a lOou suspension.
The challenge was introduced to the mice intranasally, 
whilst under ether anaesthetic. Two mice challenged with the 
10~^ dilution of B. pertussis mutant 51 died due to the 
anaesthetic. The numbers of mice remaining alive at the end 
of the experiment are shown in brackets at the ends of the 
growth curves. [See Section 2. vi.d.].
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counts from each group, and spleen weights (as a percentage of body 
weights) are shown in Table 12, while lung weights as a percentage of 
total body weight and lung pathologies are shown in Table 13,
The results show B. pertussis 18-323 clearly to be a virulent 
strain, mice surviving the challenge still being infected after 3 
weeks. Wellcome 28 was shown to be a weakly virulent strain, with some 
mice showing signs of infection, including increased lung weights. 
BP348 was shown to be an avirulent strain, with only very slightly 
increased lung size, but with leukocyte counts and spleen size closely 
related to the unchallenged controls. The test isolate 51 was also 
shown to be avirulent, with spleen and lung weights unaffected by 
infection, but with some increase in leukocyte numbers.
3.vii.c. Vaccine production and protection studies in infant mice
Heat-killed, whole-cell vaccines were prepared from B. pertussis 
Wellcome 28, BP347 and mutant 51. The vaccines were injected into
Infant mice in randomised groups. The mice were later challenged with 
B. pertussis 18-323, either intracerebrally (ic) or intranasally (in). 
Two groups of mice were left unvaccinated in each test. The first 
unvaccinated group received the challenge, the second group /went 
unchallenged. Mice which died immediately after the challenge were 
classified as deaths due to anaesthesia.
After ic_ challenge no mice vaccinated with B, pertussis Wellcome 
28 died. However, fatalities were observed in mice vaccinated with 
both BP347 and mutant 51 vaccines. Fatalities were also observed with 
challenged mice which had not been vaccinated.
After in. challenge experiments, infection was monitored by weight 
gain, lung pathology and lung weights. The lung weights were expressed
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Table 12 Leukocyte counts and spleen weights from mice
challenged with B, pertussis strains
Groups of five mice challenged with different strains 
of B. pertussis in a mouse-weight-gain test, and a set of 
unchallenged mice, were examined to identify leukocyte 
counts and spleen weights (as a percentage of body weight) 
three weeks after the initial challenge.
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Challenge strain Dilution Mean leukocyte count <+/-SD> 
(per mm=)
18-323 10-= 15982 +/_ 4999
Mutant 51 10-1 14446 +/_ 2097
Wellcome 28 10-' 12727 +/_ 3005
BP348 10-' 8735 +/_ 2427
Unchallenged 6852 +/_ 1582
Challenge strain Dilution Mean spleen weight (+/-SD)
(as a % of total body weight;
18-323 10-= 0.622 +/_ 0.254
Unchallenged 0.584 +/_ 0. 108
Wellcome 28 10-' 0. 519 -*■/_ 0. 138
BP348 10-' 0. 409 '*■/„ 0, 058
Mutant 51 10-' 0.387 +/_ 0.078
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Table 13 Lung weights and pathologies from mice challenged
with B. pertussis strains
Groups of five mice challenged with different strains 
of B. pertussis in a mouse-weight-gain test, and a set of 
unchallenged mice, were examined for lung pathology <0 - 
normal, 4 - heavy infection) and maintenance of the
challenge strain (A). Increases in lung weights <B; as a 
percentage of body weight) three weeks after the initial 
challenge were noted as a sign of virulence in the challenge 
st rain.
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A.
Challenge
strain
Mouse
1 2 3 4 5
18-323 Lung pathology 2 1 0  4 4
Lung culture + ++ “ + +++
Wellcome 28 Lung pathology 0 3 0 4 1
Lung culture — — ++ — —
BP348 Lung pathology 0 0 0 0 0
Lung culture — — — — —
Mutant 51 Lung pathology 0 0 0 0 0
Lung culture — — — — —
Unchallenged Lung pathology 0 0 0 0 0
Lung culture — —
B.
Challenge strain Dilution Mean lung weight C+/-SD) -
(as a % of total body weight)
18-323 10-= 1. 914 0. 621
Wellcome 28 10-' 1. 432 0. 305
BP348 10-' 1, 162 +/_ 0. 398
Mut ant 51 10-' 0,820 +/_ 0.058
Unchallenged 0.798 +/_ 0.222
1 2 9 -
as a percentage of the whole body weight and the average value (for 
each group) was calculated with standard deviations (Figure 17). At a 
vaccine dose of 2ou. ml vaccines made from both Wellcome 28 and mutant 
51 showed good protection (low lung weights as a percentage of total 
body weight), whilst the BP347 vaccine showed little protective 
activity, Unvaccinated mice in this test showed lung weights of less 
than 1% of body weight when unchallenged, and up to 4. 5% of body
weight when challenged with virulent B. pertussis. Lung pathologies of 
mice vaccinated with B. pertussis Wellcome 28 were clear where high 
vaccine doses were given, but signs of infection were present where 
lower doses were used. Similar lung pathologies were seen in mice
vaccinated with mutant 51, However, in mice vaccinated with the 
avirulent mutant BP347 the lungs showed signs of heavy infection.
3. vii.d. Antigenic modulation
Haemolytlc colonies of B. pertussis Wellcome 28 and mutant 51 were 
picked from BG overlay plates and restreaked on the same media. Plates 
were incubated in a moist environment at 25"C to induce antigenic 
modulation. Under these conditions B. pertussis Wellcome 28 grew as
non-haemolytic colonies, while mutant 51 retained haemolytlc activity.
Additionally, mutant 51 showed haemolytlc activity on BG sandwich 
plates containing 20mM MgSO* when grown at 37'C, whereas under these 
conditions B. pertussis Wellcome 28 was non-haemolytic.
3. vii. e. E.cp'Rl digests of Crb~~ mutants probed with the adenylate 
cyclase operon on pRMBll 
A Southern blot of digests of the chromosomal DNA from the
Crb~ mutants was probed with pRMBll [see Fig. 21 to identify genetic 
rearrangements or transposable genetic element insertions in the Crb~
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Fig, 17 Mouse intranasal protection test
Vaccines from B. pertussis Wellcome 28 (A; positive
control), BP347 (C; negative control), and the transposon
mutant 51 <B; test isolate) were injected into infant mice
in randomised groups. The mice were subsequently challenged 
in with B. pertussis 18-323. Groups of unvaccinated mice were 
either challenged (E), or left unchallenged CD).
The graph shows the mean lung weights of the mice two 
weeks after the challenge date, as a percentage of the 
average body weight per group. Standard deviations were 
calculated as a measure of variation and are shown on the 
graph as broken lines.
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mutant 51, which could have caused constitutive expression of the 
haemolysln gene, A film was exposed to the radiolabelled probe on the 
filter for 2 days at -70'C and then developed (Figure 18). However, 
the presence of a repeated DNA sequence upstream of the cyclase operon 
renders the analysis of genetic insertions with this clone 
impractical.
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Fig. 18 Southern blot of chromosomal DNA from Crb~ mutants 
probed with part of the adenylate cyclase operon 
on pRHB11
The clone pRMBll C see Figure 23, which contains the 
5. 5kb Clal fragment subcloned from pRMBl, was radiolabelled 
by nick-t ranslation and used to probe a Southern blot of 
EcoRI digested B. pertussis strains including the transposon 
mutant 51. This subclone contains the start of the cyclase 
open reading frame, and the repeat sequence IS481vl (McPheat 
et al. , 1989).
The blot shows the wild-type pattern found when probing 
B.pertussis Wellcome 28 (#28), and the apparently identical 
banding patterns found In the transposon mutants created in 
this study. The approximately 12kb EcoRI fragment covering 
pRMBll, where an IS element insertion may be present in 
mutant 51, cannot be distinguished from the repeat sequence 
pat t ern.
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4.1. Tng Delivery Vectors for Insertional Mutagenesis of
Bordet el 2 a pertussis
The considerable success of Weiss et al, (1983) in using Tn5 
mutagenesis to study pathogenicity in B. pertussis indicated that this 
technique could yield Information about virulence in other bacterial 
pathogens. Since this report, generalised transposon mutagenesis has, 
amongst other work, been used to identify protease-deficient strains 
of Aeromonas hydrophile (Leung and Stevenson, 1988), exoprotease genes 
in Pseudomonas aeruginosa (Stapleton et al. , 1984) and mutants of
Salmonella lacking a virulence-associated characteristic (Finlay et 
al. t 1988). This present study with TnS" mutagenesis was aimed at the 
further elucidation of the mechanisms of virulence regulation in 
B, pertussis.
The proficient use of Tn5 in mutagenesis depends on the recipient 
bacterial .strain having no Intrinsic resistance to the antibiotic 
resistance gene(s) carried on the incoming transposon. Since several 
studies have successfully introduced the kanamycin resistance-encoding 
transposon Tn5 (or one of its many derivatives) into B. pertussis'L see
Section l.viii.d.], the level of spontaneous kanamycin resistance in
\
this pathogen was considered to be suitably low. This study re­
confirmed that both B. pertussis Wellcome 28 and Tohama strains were 
suitable for Tn5 mutagenesis by virtue of negligible intrinsic 
resistance to kanamycin.
The original studies of Weiss et al. (1983) on B. pertussis 
virulence genes Involved the use of plasmid pUW964, which incorporates 
the ColEl replTcon, for transposon carriage into strain Tohama.
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Preliminary work for this study indicated that this 'suicide' vector 
might be unsuitable for Tn5" delivery into B. pertussis Wellcome 28 
after the identification of transconjugants maintaining pUW964, Simon 
(1989) reported that the efficacy of transposon donors varies even
between closely related strains, which could indicate why pUW964 was 
maintained in strain Wellcome 28. However, further studies revealed 
that some transconjugants of strain Tohama also maintain this 
particular vector. It appears that the inability to transform 
B, pertussis with ColEl as reported by Weiss and Falkow (1982) does not 
mean that the repllcon is entirely inactive in this bacterium when 
introduced by conjugation as part of a larger chimaeric plasmid.
The maintenance of transposon delivery vectors could, on
analysis, produce both complex and confusing data and their effective 
use in transposon mutagenesis experiments would require labour 
intensive screening of transconjugants to exclude all those still 
containing the delivery vectors. Such methods may have been used in 
the early experiments of Weiss and co-workers, although this was not
reported in either of their papers on Tn5" mutagenesis (Weiss et al. ,
1983; Weiss and Falkow, 1983). To facilitate the continuation of'this 
study, alternative Tn5 delivery vectors, with different genetic 
backgrounds to pUW964, were introduced into B. pertussis Wellcome 28, 
to identify a truly suicidal plasmid suited for mutagenesis.
The most important characteristics of a transposon delivery 
vector are a high transfer frequency from the B, coll donor strain into 
the recipient species, combined with an inability to replicate once 
transferred. The transposon carriers pJB4JI and pSUP2021 used in this 
study, either incorporate, or can be mobilised by, the broad-host-
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range IncP group transfer (ira) genes. The ira genes for the 
mobilisable vector pSUP2021 are integrated within the chromosome of
r\
the E. cold donor strain S17-1 (Simon et al., 1983). However, this^did 
not mobilise pSUP2021 into B. pertussis at detectable levels and this 
system was not used further. In contrast, the transposon delivery 
vector pJB4JI transferred into B. pertussis Inducing kanamycin 
resistant transconjugants at reasonably high frequencies. However, 
this plasmid was shown to be maintained in a high proportion of the 
resultant transconjugants.
The IncN group transfer genes of pGS9 and the derepressed Incl« 
group transfer genes of pLG221 conveyed the kanamycin resistance gene 
of Tn5 into B. pertussis at high frequencies, similar to that of pUW964 
transfer. The transposon donor pGS9 was, however, shown to be 
maintained in the resultant kanamycin resistant transconjugants (both 
by their acquired resistance to plasmid encoded antibiotics and by 
their hybridisation to the closely related plasmid pGSlS). The 
transposon delivery vector pLG221 was, however, shown not to be 
maintained at significant levels in B. pertussis Wellcome 28 kanamycin 
resistant transconjugants.
In the absence of mutagenesis studies using bacteriophage-based 
transposon delivery vectors, or studies using electroporation to 
introduce simple narrow-host-range plasmids carrying transposons into 
B. pertussis, this preliminary work indicated that of the transposon 
delivery vehicles tested, the Collb based vector pLG221 appeared to be 
the most useful for further Tn5 mutagenesis experiments.
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4.11. Transposon Mutagenesis of B. pertussis
The Tn5 insertion mutants of B. pertussis Wellcome 28, produced 
during this study using the transposon delivery vector pLG221, were 
classified with respect to the Congo red-binding (Orb) phenotype (as 
red or pale colony types) and to the use of selective pressure, 
against phase I organisms, used in their isolation. The majority of 
the transposon mutants created retained the ability to bind the dye 
Congo red (a characteristic associated with virulent strains of
B. pertussis; Parton, 1988).
The Crb^ Tn5 mutants were screened for the loss of expression of 
heat-labile toxin (HLT) and the loss of ability to modulate when grown 
at 25°C (since at this time no isolates with insertion mutations in 
either of these genetic loci had been produced). Mutants not producing 
HLT were desired for both genetic studies (cloning and sequencing of 
hit) and for assessment of virulence in the infant mouse model. 
Although over 200 mutants were screened this study did not identify a 
mutant solely deficient in HLT. Lodge et al, (1985) have discussed the 
identification of Tn5 insertion hotspots within target DNA molecules. 
This insertional specificity of Tn5 may have been Involved in the 
inability to produce mutants lacking HLT, both in this and in 
previously published work (Weiss et al, , 1983), although recently
Weiss et al. (1989) have used a Tn5-derived transposon to produce a 
mutant unable to express HLT.
Approximately 110 Crb’*' Tn5 mutants were screened to identify 
individual isolates which were unable to modulate during growth at 
25°C on media containing the dye Congo red. Mutants maintaining the
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Crb^ phenotype under such growth conditions would be of use in further 
studies on the mechanisms of virulence regulation in B, pertussis. 
However, no transposon insertion mutants were Identified in this study 
which were unable to modulate from the Crb* (red) phenotype to the 
Crb“ (pale) phenotype after a change from X-mode to C-mode growth 
conditions.
Spontaneous mutants constitutively expressing X-mode 
characteristics have, however, now been isolated (Knapp and Mekalanos, 
1988) and the mutation causing the loss of regulatory activity was 
suggested to be within a gene designated mod, Knapp and Mekalanos
proposed the mod gene to be distinct from the vir gene, but in close 
proximity. The recent renaming of the vir gene as part of the bvg 
locus (which is composed of three genes) suggests that mod may also be 
part of this locus. Since expression of bvgA, bvgB and bvgC has been 
shown to be required for the Vir^ phenotype (Aricô et al., 1989), an 
insertion mutation in mod (or bvgB, which has a periplasmlc sensory
protein product and is therefore most likely to correspond to mod) 
would presumably only be identifiable by the change to the Vir“
phenotype. Such a mutant would have been identified in this study as 
possessing the Crb~ phenotype. Those spontaneous mutants found by 
Knapp and Mekalanos to be constitutively expressing mod, may have been 
caused by a mutation in the region of the gene which acts as an 
environmental sensor. This would allow gene expression, but might
modify the proteins ability to act in a regulatory manner.
A number of mutants possessing the pale (Crb~) phenotype were 
identified from the bank of transposon mutants created in this study. 
None of the Crb~ mutants proved equivalent to the classical phase IV
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strains (being unable to grow on nutrient agar), but, with the 
exception of mutants 51 and 73, the Crb~ mutants did not express any 
of the virulence-associated factors tested. Parton (1988) has 
suggested that the Congo red-binding phenotype is a characteristic 
whose expression is controlled by the bvg locus. The variants created 
in this study (excluding 51 and 73) will, therefore, be considered as 
phenotypically equivalent to the avirulent (Vir~) strains described by 
Weiss et al. (1984). Mutants 51 and 73, which express only certain 
virulence factors, are considered separately in Section 4.vii.
The Crb~ mutants created during this study were divided into two 
classes, 1. those isolated from a fully supportive (non-selective) 
growth medium, and ii. those isolated after growth on a batch of Difco 
Bacto agar previously shown (C,J. Duggleby, personal communication) to 
select against phase I B, pertussis. Control plates identified a high 
frequency of spontaneous mutation to the Crb~ phenotype when
B. pertussis Wellcome 28 was grown on this selective agar. This high 
mutation rate suggests that spontaneous mutation to the Crb~ phenotype 
may be an important factor to consider in those transposon mutants (1- 
99) which underwent selective pressure against phase I
characteristics. Such mutants could have a mutation in the virulence
\
regulatory region of the chromosome, while the Tn5 insertion could be 
positioned in a region unassociated with regulatory functions [see 
later].
Mutant 102, which displayed an Intermediate Congo red-binding 
phenotype (Crb+/"), was shown to have a greatly reduced ability to 
haemagglutinate red blood cells (associated with loss of expression of 
FHA), Parton (1988) has, however, noted that a transposon mutant with
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an insertion in the fha structural gene CFha“ mutant BP353) exhibits 
the Crb^ phenotype. This suggests that the mutation causing the Fha" 
phenotype in mutant 102 may not have been due to a transposon 
insertion in the fha structural gene. This mutant also had reduced 
levels of agglutinogen 3, suggesting that the transposon insertion may 
be within genes controlling expression of surface components. 
Mekalanos (Protein Toxins Meeting, Urbino, Italy, 1989) has identified 
a transposon mutant with an Fha" phenotype which produces agglutinogen 
2 and 3 subunits, but has no fimbrial agglutinogens 2 or 3. An 
assembly or export protein which controls the surface expression of 
both FHA and agglutinogens 2 and 3 was postulated. A possible site for 
the transposon Insertion in mutant 102 would be in the gene which 
normally expresses this protein.
Alternatively, the mutation in 102 could be within genes
associated with iron uptake mechanisms, or surface hydrophobicity (FHA
being the main hydrophobic constituent of the cell; Fish et al, ,
1987), since Congo red-binding may be associated with either of these
properties. Crb" mutants of Neisseria meningitidis have been suggested
to be defective in their ability to acquire iron in vivo (Payne and
Finkelstein, 1977), while in Shigella the same authors have suggested
\
the Crb" phenotype to be involved with cell-surface iron-transport 
components. However, more recently Stugard et al, (1989) have 
suggested a cell surface attachment function for the crb gene product 
in S. flexneri.
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4.111. Tn5 Insertion Sites In Mutants Altered in the Congo red- 
Blndlng Phenotype
The region around the Tn5 insertion sites in the Crb" mutants and 
in mutant 102 were mapped for restriction sites to identify insertions 
within the bvg locus, or homologous regions of Insertions between
mutants. Similarities in the sites of insertions were used to 
subdivide the mutants into potentially related groups, and to pin­
point loci at which Tn5 insertions could have produced the Vii—
phenotype. The site of insertion in the Crb^^" mutant 102 was analysed 
after restriction mapping to position the transposon either within the 
known fha genes or at an unknown locus Csee Section 4.ii.].
The Tn5 insertions in the Crb" mutants 100 and 101 were shown to
be within a BamHI fragment of the same size (15kb) as the interrupted
fragment in Weiss's mutant BP347 [see Fig. 4], Due to the internal 
BamHI restriction site in TnS', the insertions in mutants 100 and 101 
could be accurately positioned to an area just upstream of the 
insertion site in BP347, but still within the bygC gene (Figure 19). 
This orientation of the insertion sites was confirmed by a comparison 
of the interrupted Sail and EcoRI restriction fragment sizes (0.6kb 
and 2.5kb respectively in mutant 100 and 0.3kb and 2.5kb respectively 
in mutant 101) with the published bvg restriction map.
The site of the transposon Insertion in mutant 113 was localised 
to a BamHI fragment of approximately 14kb. However, the similarity in 
size to the 15kb BamHI fragment interrupted in mutants 100 and 101 
appears coincidental since the interrupted EcoRI fragment in mutant 
113 is 9. 3kb in size and such a restriction fragment does not appear
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Fig. 19 Restriction map of the bvg locus showing Tn5 Insertion 
sites identified in the Crb" mutants 100 and 101
The bvg locus was defined by Arico et al. (1989) and the 
figure shows EcoRI (E) and Sail (S) sites covering the three open 
reading frames bvgh, bvgB and bvgC. The Tn5 insertion site in 
BP347 is shown within the 2.7kb EcoRI fragment and the l.Okb Sail 
fragment. The transposon insertion sites in mutants 100 and 101 
(isolated in this study) are shown in the 2. 5kb EcoRI fragment 
and in the 0.6kb and 0.3kb Sail restriction fragments 
respectively. The locations of these insertion sites were 
determined from Figures 11, 12 and 13. Mutants 100 and 101 were
identified from non-selective media by virtue of the Crb" 
phenotype.
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in or around the bvg locus. The Vir" phenotype displayed by this 
mutant is, therefore, unlikely to be due to an insertion mutation in 
the known virulence regulatory locus and appears to be in a region 
unrelated to the insertion sites found in the other Crb" mutants.
Mutants 51, 73, 97, 98 and 99 all have Tn5 insertion sites within 
a BamHI restriction fragment of approximately 30kb. The Sail- and 
EcoRI-Interrupted restriction fragments for these mutants show that 
two pairs of mutants, 51 and 73, and 98 and 99, have identical 
insertion sites. Each pair were isolated from the same filter mating 
and can therefore be considered as clones. Analysis of the simple 
restriction maps constructed around the transposon insertions in 
mutants 51, 97 and 98 suggests that, either, the mutations are widely
spaced along a single BamHI fragment, or that the transposon 
insertions are within different BamHI fragments of approximately the 
same size. In mutant 97 the transposon Insertion was positioned not 
only in a large BamHI fragment, but also within large Sail Cllkb) and 
EcoRI (10,8kb) restriction fragments, indicating that the interrupted 
locus is unrelated to those found in mutants 51 and 98. In mutant 98 
the BamHI restriction site within Tn5 has allowed the positioning of
the transposon to a site very near the end of the 30kb fragment
\
(approximately Ikb from one end), while in mutant 51 the transposon 
has been identified in a more central position (at least 9kb from one 
end), indicating that even if the transposons have inserted in the 
same restriction fragment, the sites of insertions in these two 
mutants are at least 8kb apart.
Large sized BamHI fragments (of approximately 40kb) were 
identified containing transposon insertions in mutants 15, 104 and
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268. The internal BamHI site of Tn5 allowed the positioning of the 
insertions in these fragments to within a central region (although the 
large sizes involved makes analysis difficult). Data from the Sall- 
interrupted fragments show the Tn5 insertions in mutants 15 and 268 to 
be within 7.Okb fragments Csee Table 8], Indicating that the mutations 
in these isolates could be closely related. The internal Sail site in 
Tn5 allowed the positioning of these Insertions to, either, near one 
end of the fragment, or, alternatively, at opposite ends of the 7. Okb 
fragment. The Tn5 hybridisation data from the EcoRI digests of both 
mutants showed the insertions not to be in the same sized EcoRI 
fragments and, therefore, most probably at alternate ends of the 
interrupted Sail fragment (Figure 20). The Tn5 Insertions in mutants 
15 and 268 appear to be within approximately 7.Okb of each other. This 
distance is not, however, truly indicative of an alternative locus 
possibly involved in the regulation of virulence factor expression. 
The Tn5 insertion site in mutant 104 was shown to be in a different 
40kb BamHI fragment from those in mutants 15 and 268 since the 
transposon was also shown to be centrally positioned in a large (251<b) 
Sail fragment.
The Crb" mutant 115, showed no similarities in the site of Tn5 
insertion with the other Crb" mutants. As such, this mutant (and 
others with similarly individual insertion sites) is unlikely to have 
an insertion mutation within a novel virulence-regulatory locus. 
However, only on the identification of the uninterrupted gene in a 
gene library, followed by the réintroduction of the functional gene 
into the mutant, could the true effect of the transposon mutation be 
resolved. The possibility of having isolated spontaneously Vii—
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Fig. 20 Proposed restriction map of the area surrounding
the Tn5 insertion sites in Crb" mutants 15 and 268
The map shows a possible arrangement of BamHI (B), 
EcoRI (E) and Sail (S) sites surrounding the Tn5" insertions 
in mutants 15 and 268. The map has been constructed from 
information in Figures 11, 12 and 13 Csee Table 81.
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mutants with Tn5' insertions at sites unassociated with virulence 
regulation must be considered.
The Crb^/- mutant 102 shows a restriction pattern around the Tn5 
insertion site (Figure 21) which is different from the map of the 
known fba locus (Brown and Parker, 1987). This suggests that the 
mutation is not within the fha structural gene, nor in those genes 
involved with export functions, but possibly at a locus involved in 
the control of expression of surface characteristics [see Section 
4. ii. ].
The Southern blots used to identify the sites of Tn5 Insertions 
in the Crb~ mutants show the presence of more than the expected number 
of hybridising bands in some of the mutant DMA digests, after a Hpal 
restriction length fragment probe of Tn5 was employed (the Hpal 
fragment of Tn5 covers both ISS’O elements, whereas the Hindi 11 
fragment does not). The additional bands suggest that IS50R has been 
transposing Independently of Tn5, as has been previously reported in 
other bacterial species (Berg et aJ. , 1982). One mutant, 104, shows
the presence of a large number of additional transposition events 
within it's genome. The presence of multiple copies of the 'same 
transposable genetic element in a single genome is known to cause 
inversions or deletions of DMA and the possibility of genetic 
rearrangements must be considered in any analysis of mutant 104. The 
IS50 insertions within EcoRI sites have been identified by a 
comparison of blots probed with the Hindlll fragment of Tn5, then 
reprobed with the Hpal fragment. The ISS'O insertions in mutants 97 and 
268 are within fragments possibly associated (by size; 2, 7kb and 2. 9kb 
respectively) with similarly sized fragments in the bvg locus (2 .5kb
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Fig. 21 Restriction map of the region surrounding the Tn5 
Insertion site in mutant 102
The restriction enzyme BamHI (B), EcoRI (E) and Sail <S) 
sites around the Tn5" insertion in the Crb^^" mutant 102 are 
shown. Both possible orientations of the interrupted Sail 
fragment, with respect to the BamHI fragment are indicated, one 
above (fragmented line) and the other below (solid line). The 
possible extreme positions for the EcoRI interrupted fragment are 
also shown, separate from the restriction map and with arrows to 
denote their imprecise positioning. This map may represent a 
novel locus potentially involved with control of expression of 
cell surface components.
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and 2. 7kb EcoRI fragments). Reprobing the blots with pRMB2 (which 
contains the cloned bvg locus) would identify IS50 insertions within 
this region by the additional 1. 5kb fragment size associated with 
insertions of this element Csee later].
The apparent high frequency of 1S50 transposition in B,pertussis 
seen in this study, makes analysis of mutants complex. However, the 
events described here had not been noted by other workers introducing 
Tn5 into this pathogen and have been described as only rare events in 
other bacteria (Simon, 1989). This suggests that the particular 
recipient strain used in this study may be the cause of this problem, 
or that previous studies have mainly ignored IS50 transposition 
events. The latter may be the case in the original studies on
B. pertussis (Weiss et al. , 1983), since Tn5 insertion sites were
identified after hybridisation studies using the internal HindllI 
fragment of Tn5 as the probe.
4.Iv. Complementation of Crb~ Mutants with the Cloned bvg Locus
The cloned bvg locus, on both the tetracycline resistant cosmid 
pRMB2 and its deletion derivative pDMl, was introduced. intcK the
B. pertussis Crb“ transposon mutants isolated during this study and
\
into Weiss's mutant BP347. All the Crb” mutants could be complemented 
in trans to the Crb'*' phenotype on introduction of the cloned bvg 
locus. Additionally, the non-haemolytic Crb~ mutants complemented” in 
trans with either pRMB2 or pDMl regained haemolytic activity. The 
reversion of the Crb~ transposon mutants to the Crb'*' phenotype 
associated with phase I organisms when complemented in trans with bvg 
suggests that all the mutations associated with loss of virulence
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characteristics were situated within the bvg locus.
Some of the tetracycline resistant transconjugants of the Crb“ 
mutants did not, however, regain the ability to bind Congo red dye. 
This Instability of the hvg-containing clones may have been caused by 
loss of the insert on repeated subculture, a high spontaneous mutation 
rate to the bvg~ genotype by the previously described mechanism of 
frameshift mutagenesis (Stibitz et al., 1989), or by alternative 
mechanisms. However, Lee et al. (1990) have recently suggested that 
the tetracycline resistance gene in pLAFR2 may be poorly expressed in 
B. pertussis strains. These authors suggested that the use of low 
levels of tetracycline in selective media may allow the growth of 
plasmid-free segregants. A similar situation could be occuring in this 
study with the pLAFRl-derived, tetracycline resistant plasmids pRMB2 
and pDMl.
Both pRMB2 and its derivative pDMl complemented in trans the Crb~ 
transposon mutants to Crb+ and Hly+ phenotypes, suggesting that the 
region deleted during the construction of pDMl is not Involved in the 
regulation of virulence. It has been proposed that the insert in pRMB2 
is composed of two non-contiguous fragments (McGillivray et al. , 1989)
and these studies support the positioning of the deletion mainly 
within the non-bvg encoding part of the insert.
Mutant 51 regained the Crb'*' phenotype after introduction of 
pRMB2, suggesting that this isolate has one mutation affecting the 
expression of virulence characteristics (as in the other Crb“ 
mutants), and another controlling the expression of part of the cyaA 
gene (the haemolysin). The latter could have been caused by an 
insertion of Tn5 or IS5# at the C-terminal end of cyaA. An insertion
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in this region could have caused the constitutive expression of the 
genes downstream of the insertion site due to the promoter on the end 
of IS5"0R (Berg et al. , 1980). However, the insertion within the C-
terminal part of the gene could have modified the proteins ability to 
act as an adenylate cyclase.
4. V. Mutations in the bvg Locus Causing the Crb~ Phenotype
It has been proposed that several of the Crb“ mutants isolated 
during this study have insertions, of either Tn5 or IS50, in the bvg 
locus (based on the sizes of restriction fragments interrupted by 
these mobile genetic elements - see Table 8 ). Southern blots of both 
EcoRI- and BarnHI-digested chromosomal DNA from the Crb“ mutants, when 
probed with pRMB2, showed mutants 100 and 101 to have insertions of 
Tn5 within the 2.5kb EcoRI fragment of the bvg locus. However, the use 
of pRMB2 as a probe identified no mutants with insertions of 1S50 
within the bvg locus (as proposed for mutants 97 and 268).
Hybridisation studies with the bvg locus revealed that of the
remaining eight mutants which possess the Crb” phenotype, two had 
deletions in or around this region. Mutant 97 has a small
(approximately lOObp) deletion within the 2.7kb EcoRI fragment. 
Similar deletions (of 50 - 500bp) have been identified in phase
variants of B, bronchiseptlca (Monack et al. , 1989). The identification
of a common event which causes loss of virulence properties in two
species of Bordetella suggests such a non-reversible event may be of 
importance to these pathogens. However, the reversible mechanism for 
phase variation proposed by Stibitz et al, (1989), which involves 
frameshift mutations in the bvg locus, would appear of more adaptive
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value to a pathogenic bacterium than a non-reversible one. Although
both proposed mechanisms for phase variation in B, pertussis may occur 
during the disease process, laboratory studies, on which these 
mechanisms have been based, have involved certain selective pressures 
which may have little in common with the in vivo situation.
Mutant 104 showed a much larger deletion than that in mutant 97, 
with the entire bvg locus and part of the fhaB gene excised. A number 
of additional transposition events have been proposed to have occured 
in this mutant suggesting that the deletion in mutant 104 may have 
been less likely to be a spontaneous event, associated with normal 
mechanisms of phase variation, than that in mutant 97. The mutation 
may have been caused when DNA positioned between direct repeats of the 
transposable genetic elements was deleted during a recombination event 
(Figure 22).
The remaining six mutants (15, 51, 98, 113, 115 and 268) showed
no obvious mutations in or around the bvg locus which could have
caused loss of expression of virulence-associated factors. However,
complementation studies have indicated that these isolates are
unlikely to have mutations in virulence-regulatory loci distinct 'from
the known bvg locus. These mutants may have Tn5 insertions at loci
\
uninvolved with regulation of virulence and may be Vir~ due to 
spontaneous frameshift mutations or small deletions within the bvg
locus which are not apparent on Southern blots.
4. vl. Frameshift Mutagenesis of Crb” Transposon Mutants
The spontaneous mutation of phase I B. pertussis to the variant 
(Vir“) form is a relatively infrequent event. However, the frequency
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Fig. 22 A possible sequence of events leading to the deletion 
of the bvg locus In Crb~ mutant 104
The multiple transposition events in mutant 104 indicate 
that the large deleted region in this mutant may have been caused 
by a recombination event between two closely positioned 
transposable elements. Two IS50 elements are shown positioned, 
one upstream of the bvg locus and one within the fhaB gene (A). 
Deletion of the central region by recombination CB) would produce 
a mutant with a bvg~ and fha~ genotype CO.
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of this variation has been noted to be significantly increased during 
growth in the presence of a frameshift mutagen, such as ICR 191 
(Stibitz et al. , 1989). This mutagen has been shown to cause the
insertion or deletion of single bases, pairs, or triplets of bases 
into the genomes of bacteria (Miller, 1972).
After growth for 48 hours in the presence of ICR 191 a culture of
B. pertussis Wellcome 28 showed a ratio of Crb-;Crb+ phenotypic types
of 1:3000. Reversion of the Crb~ variants produced in this manner 
would presumably occur at similar frequencies, as noted in the Tohama 
strain (Stibitz et al. , 1989). However, the spontaneous Crb~ variant
used in this study, B. pertussis L84 phase I Crb~, showed no reversion 
to phase I characteristics after growth in ICR 191. This spontaneous 
mutant may have arisen by a mechanism unassociated with frameshift 
mutations (perhaps by a small deletion in the bvg locus - see
previously).
The Crb~ transposon mutants isolated during this study, which
have been identified with transposon insertions (mutants 1 0 0 and 1 0 1 ) 
or deletions (mutants 97 and 104) in the bvg locus, were shown (as 
expected) not to revert to the Crb^ phenotype after growth in' the 
presence of ICR 191. Mutants 51, 98 and 113, which have no obvious
mutations in the known virulence regulatory genes, could also not be
induced to revert to the Crb'*' phenotype after growth in liquid
cultures containing ICR 191. Hence, these mutants cannot be considered 
to have arisen by point mutations within the bvg locus, and appear to 
have undergone an, as yet, unidentified mechanism of variation.
Mutant 15, when grown for 48 hours in liquid cultures containing
0. 7[ig/ml of ICR 191, showed reversion to the Crb^ phenotype; a ratio
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of Crb*"; Crb“ phenotypic types of 1:4000 was noted. This suggests that
the Wellcome 28 strain, in common with the Tohama strain, undergoes
frameshift mutations within the bvg locus to produce variants lacking 
virulence-associated factors. However, mutant 15 was originally 
isolated on a medium which selects against phase I organisms. Control 
experiments previously showed that this selective pressure may induce 
variants, as the spontaneous mutation rate on this mediiura was high
[see Section 3. ii.b.], again indicating that the identification of
frameshift mutants of B, pertussis under such conditions may have 
little to do with the in vivo situation.
Mutants 115 and 268 were not tested for the ability to revert to 
the Crb'* phenotype after growth in ICR 191-containing media. Although 
these mutants were originally isolated without selective pressure, the 
possibility that they have arisen by frameshift mutation cannot be 
dismissed,
4. vii. Studies on Mutant 51
Mutant 51 (and the identical isolate 73) was originally 
identified as a Crb~ transposon insertion mutant from media selective 
against phase I characteristics. Interestingly, the mutant was unable 
to haemagglutinate red blood cells and did not produce agglutinogens 2 
and 3, heat-labile toxin, pertussis toxin and X-mode specific 
polypeptides, but retained haemolytic activity. The qualitative 
adenylate cyclase assay (C.J. Duggleby, personal communication) 
suggested that the entire cyclolysin was being expressed. However, the 
more sensitive quantitative cAMP assay (Amersham) showed no cAMP 
production by mutant 51, indicating that perhaps only a truncated form
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of the cyclolysin was being produced in this mutant.
The cya operon of B. pertussis has been cloned and mapped for 
sites of restriction enzymes (Glaser et al. , 1988a; Brownlie et ai,,
1988). The known restriction map [see Fig. 2] does not correspond to 
the simple restriction map constructed around the Tn5 insertion site 
in mutant 51. Hence, an insertion of Tn5, as the cause of the 
constitutive haemolytic nature of this mutant, seems unlikely. 
However, an 1S50 insertion has been identified in an EcoRI fragment of 
approximately 13kb in the genome of mutant 51 [see Table 81. A 
similarly sized fragment (1 2 kb) is present in the cya operon, 
suggesting that the constitutive expression of a truncated form of 
cyaA may have been caused by the insertion of IS5GR near the start of 
this gene. The identification of the proposed IS5G insertion in the 
cya operon by using radiolabelled pRMBll DNA (a subclone of pRMBl - 
see Fig. 2) as a probe proved unsuccessful due to the presence of a 
repeated DNA sequence in the cloned fragment.
The presence of repeated DNA sequences in the genome of
B. pertussis provides another alternative explanation for the
expression of single virulence-associated factors normally under
positive regulatory control. Stern et al. (1984) have suggested that
\
repeated DNA sequences may play a role in chromosomal rearrangements, 
with recombinational events placing intact structural genes under the 
control of new regulatory regions. However, further studies are 
required on mutant 51 to identify exactly which genes (complete or 
truncated) are being transcribed and the event which has lead to the 
constitutive expression of these genes.
Animal studies on mutant 51 have suggested this strain to be
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avirulent in an infant mouse model. Mice were challenged ln_ after 
ether anaesthesia and weights checked over a three week period. Those 
challenged with mutant 51 showed growth patterns equivalent to those 
found in the avirulent control (BP347). Post-infection studies showed 
that mice challenged with mutant 51 had normal spleen and lung 
weights, but with slightly increased leukocyte counts.
Additionally, mice immunised with a vaccine made from mutant 51 
appeared to be protected after in. challenge with B. pertussis 18-323, 
although no protection was derived after ic_ challenge. These 
preliminary experiments require confirmation through further studies, 
but do suggest that the haemolysin could be a protective antigen and 
as such should be considered as a future component of sub-unit 
vaccines. Bacillus anthracis has an adenylate cyclase with regions of 
good homology to the B. pertussis enzyme CEscuyer et aJ. , 1988). Both
enzymes require an attachment factor to facilitate entry into 
eukaryotic cells, and in B, anthracis, the attachment factor is a known 
protective antigen (PA), which is used in current vaccines.
4.vlli. Transposon Mutagenesis of Virulence Regulatory Genes 
In B. pert ussis
\
The mutants which were isolated during this study, after loss of 
the Congo red-binding phenotype, have been classified with respect to 
the type of mutation (transposon insertion, point mutation or 
deletion) shown to have been the cause of this variation (Table 14). 
Several of the mutants remain with unknown mechanisms having caused 
the loss of virulence-associated factors. However, no data has 
indicated that these mutants have arisen by transposon Insertions
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Table 14 Events causing the Crb~~ phenotype In transposon 
mutants of B. pertussis Wellcome 28
Transposon Insertions in the known virulence regulatory
locus were identified using the bvg^encoding plasmid pRMB2 as a
probe, as were deletions in this locus. Mutants caused by
frameshlfts in bvg were Identified with the frameshift mutagen 
ICR 191 which caused reversion to the Crb"* phenotype. The mutants 
with unidentified mechanisms causing the Crb" phenotype may have 
been caused by small deletions within the bvg locus which are 
undetectable on Southern blots, or alternative unidentified 
mechanisms. No common Tn5 insertion sites were identified in
these mutants which makes it appear unlikely that there is an 
alternative locus controlling virulence in B, pertussis.
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Crb" Mutants Jylutatlonal Event
15 Frameshift mutation in 
locus
the bvg
51 / 73 Unknown
97 lOObp deletion in bvgC
98 / 99 Unknown
1 0 0 Tn5 Insertion in bvgC
1 0 1 Tn5 insertion in bvgC
104 Deletion of the entire bvg locus
113 Unknown
115 Unknown
268 Unknown
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within a virulence-regulatory locus independent of bvg. Although no 
other regulatory loci have been identified, a second mechanism for 
phase variation (associated with the non-reversibility of this event) 
has been suggested to involve small deletions in the bvg locus. The 
adaptive value of such a mechanism is only suggestive of an alternate, 
as yet unidentified, environment for B, pertussis. Further studies on 
the vrg (.yir repressed g.enes) may yet provide information on the site 
of this alternative environment.
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Appendix 1 - Media Preparation
a. Stainer and Scholte basal medium with heptakis (2.6-0-dimethyl) 
B-cyclodextrin (SS(MepCD))
L-glutamate (monosodium salt) 53.Ig
L-proline 1.2g
Sodium chloride (NaCl) 12.5g
Potassium dihydrogen orthophosphate (KH^PO*) 2.5g
Potassium chloride (KCl) l.Og
Magnesium chloride (I^Clz. SH^O) 0. 5g
Calcium chloride (CaCl^.BH^O) 0.Ig
Tris (hydroxymethyl)-aminomethane 30. 5g
Heptakis (2,6-0-dimethyl p-cyclodextrin (MepCD) 5. Og
Media was adjusted to pH7. 4 by the addition of concentrated HCl, 
made up to the final volume with distilled water (5.0 litres or 1.0 
litre for 5x concentrate), autoclaved and stored at 4°C.
b. Cyclodextrin solid medium (CSM)
CSM was prepared from SS(MeBCD) by the addition of 15g/l Difco 
Bacto agar.
\
c. Casamino acids (CAA)
Casamino acids (Difco) were prepared as a 25% (w/v) solution in 
distilled water, autoclaved and stored at 4’C (alternatively casein 
acid hydrolysate (peptone No. 5) (Gibco) was used). Casamino acids were 
added to SS(MepCD) or CSM to a final concentration of 1%.
d. Supplement
Growth supplements were added to SS(MepCD) and CSM at 1ml/100ml.
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L-cysteine monohydrochloride 
Ferrous sulphate (FeSO^. 7H^0) 
Ascorbic acid 
Nicotinic acid 
Glutathionine (reduced)
400mg 
1 0 0 mg 
2 0 0 mg 
40mg 
ISOOmg
1 0 0 ml in distilled water 
Supplement was passed through a disposable Millipore filter (pore 
size 0.22pm) into sterile universels and stored at 4“C, In media 
containing the dye Congo red, the concentration of ferrous sulphate 
was Increased 10-fold.
e. Bordet-Gengou agar (BG)
BG agar (Gibco 40g/l) was prepared by the addition of glycerol 
(lOg/1 ) and distilled water, then autoclaved. Media were allowed to 
cool to 40-50’C prior to the addition of 15% defibrinated horse blood 
(InterMed), then poured.
f. Nutrient agar (NA)
NA (Oxoid) was prepared using 28g/l in distilled water.
g. Casamino acid freezing solution 
Casamino acids
Magnesium chloride (MgCl^. GH^O)
Calcium chloride (CaCl^. 2 H2 O)
Sodium chloride (NaCl)
Glycerol
lOOOmg 
lOmg 
1 . 6 mg 
500mg 
2 0 ml
1 0 0 ml in distilled water 
Solution was adjusted to pH7, 1, autoclaved and stored at 4°C.
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Appendix 2 - Buffers and Solutions for DNA Techniques
a. Tris - EDTA buffer (TE)
lOmM Tris-HCl pH8 . 0
ImM EDTA
b. Equilibrated phenol/chloroform
Phenol was equilibrated three times with an equal volume of 0.5M 
Trls-HCl pH8 .0, allowing the aqueous layer to separate and be removed. 
Equilibrated phenol was mixed with an equal volume of chloroform.
c. Brl.i. /DOC solution 
1% C«/^) BriJ 58
0. 4% <'"/v) sodium deoxycholate 
lOmM Tris pH8 . 0
ImM EDTA
d. Loading buffer 
10% (-/^> Ficoll
0. 05% (*Yv) bromophenol blue 
0 , 005% xylene cyanol
0.05% (*Y^) orange G
\
e. 20x SSC
3M sodium chloride
0. 3M trisodium citrate pH7.0
f. E buffer (TAE)
40mM Tris-base pH8 . 2
ImM EDTA
(pH using glacial acetic acid)
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g. B buffer (THE)
90mM Trls-base 
90mM boric acid
2. 5mM EDTA pH8 . 2
h. Vacublotting solutions 
Depurination solution 0. 25M HCl
Denaturing solution 1. 5M NaCl
0. 5M NaOH
Neutralising solution l.OM Tris-HCl
2.0M NaCl pH5.0
Transfer solution 20x SSC pH7. 0
i. Pre"/hybridisation solution 
50mM Tris-HCl, pH8 . 0
1. OM NaCl
50% formaraide (Fluka)
lOx Denhardt's solution (see below)
1% («/^) SDS
0 . 1% tetra sodium pyrophosphate 
lOOfig/ml prebolled salmon sperm DNA 
j. 50x Denhardt's solution
\
0.1% ("/v> bovine serum albumin fraction V 
0. 1% (~/_) Ficoll
0.1% ("Y^) polyvinylpyrrolidone 
6 x SSC
k. Oligonucleotide labelling buffer (OLE)
Solutions A, B and C were mixed in the ratio 100:250;150 and stored at 
-20'C.
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Solution A: 1ml Solution 0 (see below)
ISjjLl p-mercaptoethanol 
SjjlI dCTP (lOOmM in TE)
5)jil dTTP (lOOmM in TE)
5pl dGTP (lOOmM in TE)
Solution G: 1. 25M Trls-HCl
0. 125M MgCl^ pH8.0
Solution B: 2M Hepes pH6 . 6 (using 4M NaOH)
Solution C: Hexadeoxyribonucleotides (Pharmacia) suspended in TE to
90 OD units per ml.
1. STOP buffer 
20mM NaCl 
20mM Tris pH7. 5 
2mM EDTA 
0.25% SDS 
IpM dATP 
m. TES buf f er
lOmM Tris-HCl, pH8 . 0 
ImM EDTA 
lOOmM NaCl 
n. Nlck-translation buffer (xlO)
0. 5M Trls-HCl, pH7. 2 
0. IM MgSOa 
ImM dithiothreitol 
500pg/ml BSA (fraction V)
Store at -20"C
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o. DNase I
A stock solution containing Img/ml of DNase I in 0. 15M NaCl and 
50% glycerol was prepared, divided into small aliquots and
stored at -20°C.
p, Restriction enzyme buffers (xl)
REact^M 2 - 50mM Tris-HCl, pH8 . 0
lOmM MgCl=
50mM NaCl 
REact^M 3 - 50mM Tris-HCl, pH8 . 0
lOmM MgCla 
lOOmM NaCl 
REactTM 10 - lOOmM Tris-HCl, pH7. 6
lOmM MgCla 
150mM NaCl 
Medium salt - lOmM Trls-HCl, pH7,5
lOmM MgClg 
50mM NaCl
ImM dithiothreitol
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